menu
    • menu
    [{"orgOrder":0,"company":"Saisei Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Saisei Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saisei Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Saisei Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mabpharm","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"ACE-MAB","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mabpharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabpharm \/ Sorrento Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Mabpharm \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Signature Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Signature Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Signature Biologics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Signature Biologics \/ Undisclosed"},{"orgOrder":0,"company":"DeNova Research","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DeNova Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"DeNova Research \/ Allergan","highestDevelopmentStatusID":"1","companyTruncated":"DeNova Research \/ Allergan"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"ADM","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adrenomed \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Adrenomed \/ Undisclosed"},{"orgOrder":0,"company":"TriHealth","sponsor":"DoNotAge.org","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TriHealth","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriHealth \/ DoNotAge.org","highestDevelopmentStatusID":"1","companyTruncated":"TriHealth \/ DoNotAge.org"},{"orgOrder":0,"company":"Christiana Care Health Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Christiana Care Health Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Christiana Care Health Services \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Christiana Care Health Services \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast International S\u00e0rl","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mesoblast International S\u00e0rl","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast International S\u00e0rl \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Mesoblast International S\u00e0rl \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast International S\u00e0rl","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mesoblast International S\u00e0rl","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast International S\u00e0rl \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Mesoblast International S\u00e0rl \/ Undisclosed"},{"orgOrder":0,"company":"Kyberg Vital GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kyberg Vital GmbH","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyberg Vital GmbH \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kyberg Vital GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Mead Johnson Nutrition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mead Johnson Nutrition","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mead Johnson Nutrition \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Mead Johnson Nutrition \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"The Department Of Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ The Department Of Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ The Department Of Biotechnology"},{"orgOrder":0,"company":"AnGes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnGes \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AnGes \/ Undisclosed"},{"orgOrder":0,"company":"University of Adelaide","sponsor":"Enesi Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Adelaide","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Adelaide \/ Enesi Pharma Limited","highestDevelopmentStatusID":"1","companyTruncated":"University of Adelaide \/ Enesi Pharma Limited"},{"orgOrder":0,"company":"U.S. Army Medical Research and Development Command","sponsor":"Meiji Seika Pharma | Uniformed Services University of the Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Arbekacin","moa":"antibiotics obtained from Streptomyces kanamyceticus (related to kanamycin)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"U.S. Army Medical Research and Development Command","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"U.S. Army Medical Research and Development Command \/ Meiji Seika Pharma | Uniformed Services University of the Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"U.S. Army Medical Research and Development Command \/ Meiji Seika Pharma | Uniformed Services University of the Health Sciences"},{"orgOrder":0,"company":"Beech Tree Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Thimerosal","moa":"anti-inflammatory agents (salicylic acid derivatives)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Beech Tree Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Beech Tree Labs \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Beech Tree Labs \/ Undisclosed"},{"orgOrder":0,"company":"Noguchi Memorial Institute for Medical Research","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GHANA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Artemisinin","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Noguchi Memorial Institute for Medical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noguchi Memorial Institute for Medical Research \/ World Health Organization","highestDevelopmentStatusID":"1","companyTruncated":"Noguchi Memorial Institute for Medical Research \/ World Health Organization"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Drug Innovation Ventures at Emory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Drug Innovation Ventures at Emory","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Drug Innovation Ventures at Emory \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Drug Innovation Ventures at Emory \/ Undisclosed"},{"orgOrder":0,"company":"Avivagen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Beta Carotene","moa":"arotinoid derivatives","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avivagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avivagen \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Avivagen \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"antibiotics||ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ World Health Organization","highestDevelopmentStatusID":"1","companyTruncated":"University of Oxford \/ World Health Organization"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Hanoi University of Science","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Bacillus Spore","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Hanoi University of Science","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Hanoi University of Science"},{"orgOrder":0,"company":"DreamTec Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DreamTec Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DreamTec Research \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"DreamTec Research \/ Undisclosed"},{"orgOrder":0,"company":"DreamTec Research","sponsor":"Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DreamTec Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DreamTec Research \/ Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"DreamTec Research \/ Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Thai Binh University of Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Thai Binh University of Medicine and Pharmacy","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Thai Binh University of Medicine and Pharmacy"},{"orgOrder":0,"company":"National Children's Hospital, Vietnam","sponsor":"Anabio R&D","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Children's Hospital, Vietnam","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Children's Hospital, Vietnam \/ Anabio R&D","highestDevelopmentStatusID":"1","companyTruncated":"National Children's Hospital, Vietnam \/ Anabio R&D"},{"orgOrder":0,"company":"Universiti Kebangsaan Malaysia Medical Centre","sponsor":"Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MALAYSIA","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Universiti Kebangsaan Malaysia Medical Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universiti Kebangsaan Malaysia Medical Centre \/ Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia","highestDevelopmentStatusID":"1","companyTruncated":"Universiti Kebangsaan Malaysia Medical Centre \/ Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Lundquist Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lundquist Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lundquist Institute \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lundquist Institute \/ Undisclosed"},{"orgOrder":0,"company":"Manimarane Arjunan, MD,DM (Cardiology)","sponsor":"UR Anoop Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Manimarane Arjunan, MD,DM (Cardiology)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Manimarane Arjunan, MD,DM (Cardiology) \/ UR Anoop Research Group","highestDevelopmentStatusID":"1","companyTruncated":"Manimarane Arjunan, MD,DM (Cardiology) \/ UR Anoop Research Group"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Chicago \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"University of Chicago \/ Pfizer Inc"},{"orgOrder":0,"company":"PATH","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh | Shaheed Suhrawardy Medical College Hospital, Dhaka, Bangladesh | Aragen Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Paromomycin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PATH","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PATH \/ International Centre for Diarrhoeal Disease Research, Bangladesh | Shaheed Suhrawardy Medical College Hospital, Dhaka, Bangladesh | Aragen Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"PATH \/ International Centre for Diarrhoeal Disease Research, Bangladesh | Shaheed Suhrawardy Medical College Hospital, Dhaka, Bangladesh | Aragen Life Sciences"},{"orgOrder":0,"company":"H\u00f4pital Raymond Poincar\u00e9","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Alcoholic Chlorhexidine","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"H\u00f4pital Raymond Poincar\u00e9","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H\u00f4pital Raymond Poincar\u00e9 \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"H\u00f4pital Raymond Poincar\u00e9 \/ Undisclosed"},{"orgOrder":0,"company":"CES University","sponsor":"Lafrancol | Prolab SA | Cl\u00ednica Del Prado | Cl\u00ednica Comfamiliar Pereira","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"COLOMBIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cephalosporin","moa":"Bacterial DD-carboxypeptidase (Bact vanYB)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CES University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CES University \/ Lafrancol | Prolab SA | Cl\u00ednica Del Prado | Cl\u00ednica Comfamiliar Pereira","highestDevelopmentStatusID":"1","companyTruncated":"CES University \/ Lafrancol | Prolab SA | Cl\u00ednica Del Prado | Cl\u00ednica Comfamiliar Pereira"},{"orgOrder":0,"company":"Somerset Pharmaceuticals Inc","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Sulfamethoxazole","moa":"||Bacterial dihydropteroate synthase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Somerset Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Somerset Pharmaceuticals Inc \/ Premier","highestDevelopmentStatusID":"1","companyTruncated":"Somerset Pharmaceuticals Inc \/ Premier"},{"orgOrder":0,"company":"Horizon Health Network","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Horizon Health Network","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Horizon Health Network \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Horizon Health Network \/ Undisclosed"},{"orgOrder":0,"company":"Aga Khan University","sponsor":"World Health Organization | Boston University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"PAKISTAN","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aga Khan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aga Khan University \/ World Health Organization | Boston University","highestDevelopmentStatusID":"1","companyTruncated":"Aga Khan University \/ World Health Organization | Boston University"},{"orgOrder":0,"company":"Sonescence, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sonescence, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonescence, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sonescence, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Universit\u00e9 de Montr\u00e9al","sponsor":"Stryker | H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Universit\u00e9 de Montr\u00e9al","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e9 de Montr\u00e9al \/ Stryker | H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al","highestDevelopmentStatusID":"1","companyTruncated":"Universit\u00e9 de Montr\u00e9al \/ Stryker | H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al"},{"orgOrder":0,"company":"Kemin Foods LC","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Beta Glucan","moa":"Beta-glucan receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kemin Foods LC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kemin Foods LC \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"Kemin Foods LC \/ KGK Science"},{"orgOrder":0,"company":"Kemin Foods LC","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Beta Glucan","moa":"Beta-glucan receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kemin Foods LC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kemin Foods LC \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"Kemin Foods LC \/ KGK Science"},{"orgOrder":0,"company":"Vitae Health Innovation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Beta Glucan","moa":"Beta-glucan receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vitae Health Innovation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vitae Health Innovation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vitae Health Innovation \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Senhwa Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Silmitasertib","moa":"Casein kinase II alpha","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Senhwa Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ Senhwa Biosciences"},{"orgOrder":0,"company":"German Center for Diabetes Research","sponsor":"FAPESP | Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico | ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Maraviroc","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"German Center for Diabetes Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"German Center for Diabetes Research \/ FAPESP | Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico | ViiV Healthcare","highestDevelopmentStatusID":"1","companyTruncated":"German Center for Diabetes Research \/ FAPESP | Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico | ViiV Healthcare"},{"orgOrder":0,"company":"Southern California Institute for Research and Education","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Maraviroc","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Southern California Institute for Research and Education","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Southern California Institute for Research and Education \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Southern California Institute for Research and Education \/ Pfizer Inc"},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ii-Key Peptide Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generex Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generex Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Generex Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Fudan University","sponsor":"RNAcure Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fudan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fudan University \/ RNAcure Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Fudan University \/ RNAcure Biopharma"},{"orgOrder":0,"company":"Tongji University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tongji University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tongji University \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tongji University \/ Undisclosed"},{"orgOrder":0,"company":"Ehime University","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ehime University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ehime University \/ GHIT Fund","highestDevelopmentStatusID":"1","companyTruncated":"Ehime University \/ GHIT Fund"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"PharmaJet","sponsor":"Abnova","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaJet \/ Abnova","highestDevelopmentStatusID":"1","companyTruncated":"PharmaJet \/ Abnova"},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"Flu Lab","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GreenLight Biosciences","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"GreenLight Biosciences \/ Flu Lab","highestDevelopmentStatusID":"1","companyTruncated":"GreenLight Biosciences \/ Flu Lab"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"WHO","sponsor":"Government of Belgium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WHO","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"WHO \/ Government of Belgium","highestDevelopmentStatusID":"1","companyTruncated":"WHO \/ Government of Belgium"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Gylden Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"CD8+ T Cell Adaptive Vaccine","moa":"CD8","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Zosano Pharma \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"1","companyTruncated":"Zosano Pharma \/ Emergex Vaccines Holding"},{"orgOrder":0,"company":"University of California, Irvine","sponsor":"Harvard Medical School (HMS and HSDM) | Harvard Pilgrim Health Care | Hospital Corporation of America | Rush University | Cook County Health | Centers for Disease Control and Prevention | National Institutes of Health | National Institute of Allergy and I","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Irvine \/ Harvard Medical School (HMS and HSDM) | Harvard Pilgrim Health Care | Hospital Corporation of America | Rush University | Cook County Health | Centers for Disease Control and Prevention | National Institutes of Health | National Institute of Allergy and I","highestDevelopmentStatusID":"1","companyTruncated":"University of California, Irvine \/ Harvard Medical School (HMS and HSDM) | Harvard Pilgrim Health Care | Hospital Corporation of America | Rush University | Cook County Health | Centers for Disease Control and Prevention | National Institutes of Health | National Institute of Allergy and I"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Stryker","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Chlorhexidine","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Wipes","sponsorNew":"Northwestern University \/ Stryker","highestDevelopmentStatusID":"1","companyTruncated":"Northwestern University \/ Stryker"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Queen Mary University of London \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"Queen Mary University of London \/ GSK"},{"orgOrder":0,"company":"St. Joseph's Hospital and Medical Center, Phoenix","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"St. Joseph's Hospital and Medical Center, Phoenix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Swab","sponsorNew":"St. Joseph's Hospital and Medical Center, Phoenix \/ 3M Company","highestDevelopmentStatusID":"1","companyTruncated":"St. Joseph's Hospital and Medical Center, Phoenix \/ 3M Company"},{"orgOrder":0,"company":"Joseph Kim","sponsor":"Alberta Health services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Joseph Kim","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joseph Kim \/ Alberta Health services","highestDevelopmentStatusID":"1","companyTruncated":"Joseph Kim \/ Alberta Health services"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Geistlich Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Queen Mary University of London \/ Geistlich Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Queen Mary University of London \/ Geistlich Pharma"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Achilles Vaccines","sponsor":"The EU Malaria Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Malaria Vaccine","moa":"CSP","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Achilles Vaccines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Achilles Vaccines \/ The EU Malaria Fund","highestDevelopmentStatusID":"1","companyTruncated":"Achilles Vaccines \/ The EU Malaria Fund"},{"orgOrder":0,"company":"Children's Hospital Medical Center, Cincinnati","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | Emmaus Life Sciences | University of Michigan | Gabrail Cancer Center Research | University of Colorado, Denver","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1; Amidophosphoribosyltransferase; Glutamine synthetase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Children's Hospital Medical Center, Cincinnati","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital Medical Center, Cincinnati \/ National Institute of Diabetes and Digestive and Kidney Diseases | Emmaus Life Sciences | University of Michigan | Gabrail Cancer Center Research | University of Colorado, Denver","highestDevelopmentStatusID":"1","companyTruncated":"Children's Hospital Medical Center, Cincinnati \/ National Institute of Diabetes and Digestive and Kidney Diseases | Emmaus Life Sciences | University of Michigan | Gabrail Cancer Center Research | University of Colorado, Denver"},{"orgOrder":0,"company":"University of Maryland School of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Maryland School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Maryland School of Medicine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"University of Maryland School of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Qu\u00edmica Luar","sponsor":"National Council of Scientific Research, Argentina | Centro de Excelencia C\u00f3rdoba","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ARGENTINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Laboratorios Qu\u00edmica Luar","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Qu\u00edmica Luar \/ National Council of Scientific Research, Argentina | Centro de Excelencia C\u00f3rdoba","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Qu\u00edmica Luar \/ National Council of Scientific Research, Argentina | Centro de Excelencia C\u00f3rdoba"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"University at Buffalo | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Cobicistat","moa":"Cytochrome P450 3A","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ University at Buffalo | Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"University of California, San Diego \/ University at Buffalo | Gilead Sciences"},{"orgOrder":0,"company":"Novotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Panaphix","moa":"Cytokine","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Novotech \/ Undisclosed"},{"orgOrder":0,"company":"KD Pharma Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"KD Pharma Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KD Pharma Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"KD Pharma Group \/ Undisclosed"},{"orgOrder":0,"company":"Federal Medical Centre, Owo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NIGERIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sulfadoxine","moa":"Dihydropteroate synthetase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Federal Medical Centre, Owo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Federal Medical Centre, Owo \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Federal Medical Centre, Owo \/ Undisclosed"},{"orgOrder":0,"company":"London School of Hygiene & Tropical Medicine","sponsor":"Kintampo Health Research Centre, Ghana","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sulfadoxine","moa":"Dihydropteroate synthetase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"London School of Hygiene & Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London School of Hygiene & Tropical Medicine \/ Kintampo Health Research Centre, Ghana","highestDevelopmentStatusID":"1","companyTruncated":"London School of Hygiene & Tropical Medicine \/ Kintampo Health Research Centre, Ghana"},{"orgOrder":0,"company":"The University of Dundee","sponsor":"Insmed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Brensocatib","moa":"Dipeptidyl peptidase I","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Dundee","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The University of Dundee \/ Insmed","highestDevelopmentStatusID":"1","companyTruncated":"The University of Dundee \/ Insmed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clofazimine","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Rasna Therapeutics","sponsor":"Tiziana Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Acquisition","leadProduct":"Dactinomycin","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rasna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rasna Therapeutics \/ Tiziana Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Rasna Therapeutics \/ Tiziana Life Sciences"},{"orgOrder":0,"company":"Clinical Research Center Kiel GmbH","sponsor":"Dairyfem R&D | University of Natural Resources and Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Clinical Research Center Kiel GmbH","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clinical Research Center Kiel GmbH \/ Dairyfem R&D | University of Natural Resources and Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Clinical Research Center Kiel GmbH \/ Dairyfem R&D | University of Natural Resources and Life Sciences"},{"orgOrder":0,"company":"Oravital Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oravital Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oravital Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Oravital Inc \/ Undisclosed"},{"orgOrder":0,"company":"Purdue University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Purdue University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purdue University \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Purdue University \/ Undisclosed"},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"TFF Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"IRISYS, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IRISYS, LLC \/ TFF Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"IRISYS, LLC \/ TFF Pharmaceuticals"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Theralogix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Nitrofurantoin","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Brigham and Women's Hospital \/ Theralogix","highestDevelopmentStatusID":"1","companyTruncated":"Brigham and Women's Hospital \/ Theralogix"},{"orgOrder":0,"company":"AntiCancer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Methioninase","moa":"DNA methylation","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AntiCancer","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AntiCancer \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AntiCancer \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Entecavir","moa":"DNA polymerase\/reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"DelSiTech","sponsor":"DRW Venture Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FINLAND","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Entecavir","moa":"DNA polymerase\/reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DelSiTech","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"DelSiTech \/ DRW Venture Capital LLC","highestDevelopmentStatusID":"1","companyTruncated":"DelSiTech \/ DRW Venture Capital LLC"},{"orgOrder":0,"company":"MacroGenics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"MGAWN1","moa":"E protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"1","companyTruncated":"MacroGenics \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"REGN3470","moa":"Envelope glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"U.S. Army Medical Research and Development Command","sponsor":"SIGA Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"U.S. Army Medical Research and Development Command","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"U.S. Army Medical Research and Development Command \/ SIGA Technologies","highestDevelopmentStatusID":"1","companyTruncated":"U.S. Army Medical Research and Development Command \/ SIGA Technologies"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dacomitinib","moa":"Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-4 | Receptor protein-tyrosine kinase erbB-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Zhongnan Hospital of Wuhan University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dipyridamole","moa":"Equilibrative nucleoside transporter 1 | 3',5'-cyclic phosphodiesterase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zhongnan Hospital of Wuhan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhongnan Hospital of Wuhan University \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Zhongnan Hospital of Wuhan University \/ Undisclosed"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Peking Union Medical College Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"TTY BIOPHARM CO LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TTY BIOPHARM CO LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TTY BIOPHARM CO LTD \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TTY BIOPHARM CO LTD \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Changsha King-eagle Med Technology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Changsha King-eagle Med Technology","highestDevelopmentStatusID":"1","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Changsha King-eagle Med Technology"},{"orgOrder":0,"company":"Gyeonggido Business and Science Accelerator","sponsor":"CINECA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen receptor beta","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Gyeonggido Business and Science Accelerator","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gyeonggido Business and Science Accelerator \/ CINECA","highestDevelopmentStatusID":"1","companyTruncated":"Gyeonggido Business and Science Accelerator \/ CINECA"},{"orgOrder":0,"company":"Sesderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sesderma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sesderma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sesderma \/ Undisclosed"},{"orgOrder":0,"company":"Centro de Investigacao em Saude de Manhica","sponsor":"World Health Organization (Mozambique) | National Malaria Control Program, Mozambique | Instituto Nacional de Sa\u00fade, Mozambique","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MOZAMBIQUE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Centro de Investigacao em Saude de Manhica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centro de Investigacao em Saude de Manhica \/ World Health Organization (Mozambique) | National Malaria Control Program, Mozambique | Instituto Nacional de Sa\u00fade, Mozambique","highestDevelopmentStatusID":"1","companyTruncated":"Centro de Investigacao em Saude de Manhica \/ World Health Organization (Mozambique) | National Malaria Control Program, Mozambique | Instituto Nacional de Sa\u00fade, Mozambique"},{"orgOrder":0,"company":"Bayer AG","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Chloroquine Phosphate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ US Government","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/ US Government"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mefloquine","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ ZonMw","highestDevelopmentStatusID":"1","companyTruncated":"Radboud University Medical Center \/ ZonMw"},{"orgOrder":0,"company":"Universitas Padjadjaran","sponsor":"National Research and Innovation Agency of Indonesia | Prodia Diacro Laboratories P.T.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Quinine Sulfate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Universitas Padjadjaran","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitas Padjadjaran \/ National Research and Innovation Agency of Indonesia | Prodia Diacro Laboratories P.T.","highestDevelopmentStatusID":"1","companyTruncated":"Universitas Padjadjaran \/ National Research and Innovation Agency of Indonesia | Prodia Diacro Laboratories P.T."},{"orgOrder":0,"company":"University of Manitoba","sponsor":"MED XL | Winnipeg Regional Health Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ethanol","moa":"GABA(A) receptor alpha-1 (GABRA1)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Manitoba \/ MED XL | Winnipeg Regional Health Authority","highestDevelopmentStatusID":"1","companyTruncated":"University of Manitoba \/ MED XL | Winnipeg Regional Health Authority"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"University of Oxford \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"University of Oxford \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Scotia Health Authority \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nova Scotia Health Authority \/ Undisclosed"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Feinstein Institutes \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Feinstein Institutes \/ Undisclosed"},{"orgOrder":0,"company":"Albert Einstein Healthcare Network","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Albert Einstein Healthcare Network","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albert Einstein Healthcare Network \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Albert Einstein Healthcare Network \/ Undisclosed"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"NeoStrata Company | Penn Center for AIDS Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Glycolic Acid","moa":"Glucose-6-phosphate 1-dehydrogenase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Lotion","sponsorNew":"University of Pennsylvania \/ NeoStrata Company | Penn Center for AIDS Research","highestDevelopmentStatusID":"1","companyTruncated":"University of Pennsylvania \/ NeoStrata Company | Penn Center for AIDS Research"},{"orgOrder":0,"company":"Max Healthcare Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Max Healthcare Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Max Healthcare Institute \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Max Healthcare Institute \/ Undisclosed"},{"orgOrder":0,"company":"AIIMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIIMS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AIIMS \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AIIMS \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Moleculin Biotech","highestDevelopmentStatusID":"1","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Moleculin Biotech"},{"orgOrder":0,"company":"Regenexx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Platelet Lysate","moa":"Growth factor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Regenexx \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regenexx \/ Undisclosed"},{"orgOrder":0,"company":"Replicor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"REP 2139","moa":"HBV RNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Replicor","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replicor \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Replicor \/ Undisclosed"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Forigerimod","moa":"Heat shock cognate 71 kDa protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImmuPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuPharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ImmuPharma \/ Undisclosed"},{"orgOrder":0,"company":"Ume\u00e5 University","sponsor":"University of California | Mead Johnson Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Iron","moa":"Hemoglobin (HB)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ume\u00e5 University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ume\u00e5 University \/ University of California | Mead Johnson Nutrition","highestDevelopmentStatusID":"1","companyTruncated":"Ume\u00e5 University \/ University of California | Mead Johnson Nutrition"},{"orgOrder":0,"company":"Asfendiyarov Kazakh National Medical University","sponsor":"Eurasia Invest | Ministry of Education and Science, Kazakhstan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"KAZAKHSTAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Asfendiyarov Kazakh National Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asfendiyarov Kazakh National Medical University \/ Eurasia Invest | Ministry of Education and Science, Kazakhstan","highestDevelopmentStatusID":"1","companyTruncated":"Asfendiyarov Kazakh National Medical University \/ Eurasia Invest | Ministry of Education and Science, Kazakhstan"},{"orgOrder":0,"company":"Kawin Technology","sponsor":"KawinGreen Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kawin Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kawin Technology \/ KawinGreen Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Kawin Technology \/ KawinGreen Biotech"},{"orgOrder":0,"company":"Columbia University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Telaprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Trutag Technologies | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Brigham and Women's Hospital \/ Trutag Technologies | Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Brigham and Women's Hospital \/ Trutag Technologies | Gilead Sciences"},{"orgOrder":0,"company":"First Affiliated Hospital of Zhejiang University","sponsor":"Ascletis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ASC09","moa":"HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"First Affiliated Hospital of Zhejiang University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"First Affiliated Hospital of Zhejiang University \/ Ascletis Pharma","highestDevelopmentStatusID":"1","companyTruncated":"First Affiliated Hospital of Zhejiang University \/ Ascletis Pharma"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Famciclovir","moa":"Human herpesvirus 1 DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hikma Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hikma Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Famciclovir","moa":"Human herpesvirus 1 DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hikma Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hikma Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Valacyclovir Hydrochloride","moa":"Human herpesvirus 1 DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hikma Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hikma Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Valacyclovir Hydrochloride","moa":"Human herpesvirus 1 DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hikma Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hikma Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ ViiV Healthcare","highestDevelopmentStatusID":"1","companyTruncated":"University of North Carolina \/ ViiV Healthcare"},{"orgOrder":0,"company":"IRCCS San Raffaele","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"IRCCS San Raffaele","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRCCS San Raffaele \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"IRCCS San Raffaele \/ GSK"},{"orgOrder":0,"company":"Henry M. Jackson Foundation","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Henry M. Jackson Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Henry M. Jackson Foundation \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Henry M. Jackson Foundation \/ Gilead Sciences"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Brigham and Women's Hospital | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Brigham and Women's Hospital | Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ Brigham and Women's Hospital | Gilead Sciences"},{"orgOrder":0,"company":"Haitian Group for Study of Kaposi's Sarcoma","sponsor":"Gilead Sciences | Brigham and Women's Hospital | Weill Medical College of Cornell University | Analysis Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HAITI","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Elvitegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Haitian Group for Study of Kaposi's Sarcoma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haitian Group for Study of Kaposi's Sarcoma \/ Gilead Sciences | Brigham and Women's Hospital | Weill Medical College of Cornell University | Analysis Group","highestDevelopmentStatusID":"1","companyTruncated":"Haitian Group for Study of Kaposi's Sarcoma \/ Gilead Sciences | Brigham and Women's Hospital | Weill Medical College of Cornell University | Analysis Group"},{"orgOrder":0,"company":"Centers for Disease Control and Prevention, China","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Raltegravir Potassium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Centers for Disease Control and Prevention, China","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centers for Disease Control and Prevention, China \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Centers for Disease Control and Prevention, China \/ Merck & Co"},{"orgOrder":0,"company":"Southern California Institute for Research and Education","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Raltegravir Potassium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Southern California Institute for Research and Education","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Southern California Institute for Research and Education \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Southern California Institute for Research and Education \/ Merck & Co"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Raltegravir Potassium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"University of California, San Diego \/ Merck & Co"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Raltegravir Potassium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Maryland, Baltimore \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"University of Maryland, Baltimore \/ Merck & Co"},{"orgOrder":0,"company":"University of Washington","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Raltegravir Potassium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"University of Washington \/ Merck & Co"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Raltegravir Potassium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ Merck & Co"},{"orgOrder":0,"company":"Metropolis Medical","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Raltegravir Potassium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Metropolis Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metropolis Medical \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Metropolis Medical \/ Merck & Co"},{"orgOrder":0,"company":"David Garcia Cinca","sponsor":"Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"David Garcia Cinca","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"David Garcia Cinca \/ Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica","highestDevelopmentStatusID":"1","companyTruncated":"David Garcia Cinca \/ Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Darunavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Cipla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cipla \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cipla \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"European Health Authorities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Lopinavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ European Health Authorities","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ European Health Authorities"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Mills Clinical Research","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mills Clinical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mills Clinical Research \/ ViiV Healthcare","highestDevelopmentStatusID":"1","companyTruncated":"Mills Clinical Research \/ ViiV Healthcare"},{"orgOrder":0,"company":"University of Toronto","sponsor":"Ontario HIV Treatment Network | Maple Leaf Research | Unity Health Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Efavirenz","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Toronto \/ Ontario HIV Treatment Network | Maple Leaf Research | Unity Health Toronto","highestDevelopmentStatusID":"1","companyTruncated":"University of Toronto \/ Ontario HIV Treatment Network | Maple Leaf Research | Unity Health Toronto"},{"orgOrder":0,"company":"LVCT Health","sponsor":"Bill & Melinda Gates Foundation | Sex Workers Outreach Project | National AIDS Control Council | National AIDS and STI Control Programme | Health Options for Young Men with AIDS\/STI | Bar Hostess Empowerment & Support Programme | Gay and Lesbian Coalition","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"KENYA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"LVCT Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LVCT Health \/ Bill & Melinda Gates Foundation | Sex Workers Outreach Project | National AIDS Control Council | National AIDS and STI Control Programme | Health Options for Young Men with AIDS\/STI | Bar Hostess Empowerment & Support Programme | Gay and Lesbian Coalition","highestDevelopmentStatusID":"1","companyTruncated":"LVCT Health \/ Bill & Melinda Gates Foundation | Sex Workers Outreach Project | National AIDS Control Council | National AIDS and STI Control Programme | Health Options for Young Men with AIDS\/STI | Bar Hostess Empowerment & Support Programme | Gay and Lesbian Coalition"},{"orgOrder":0,"company":"R\u00e9seau Africain de Recherche sur le SIDA","sponsor":"Bill & Melinda Gates Foundation | University of Washington | Westat","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SENEGAL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"R\u00e9seau Africain de Recherche sur le SIDA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"R\u00e9seau Africain de Recherche sur le SIDA \/ Bill & Melinda Gates Foundation | University of Washington | Westat","highestDevelopmentStatusID":"1","companyTruncated":"R\u00e9seau Africain de Recherche sur le SIDA \/ Bill & Melinda Gates Foundation | University of Washington | Westat"},{"orgOrder":0,"company":"FHI 360","sponsor":"Family Health Options Kenya | Gilead Sciences | Institute of Tropical Medicine | Sex Workers Outreach Programme | University of North Carolina, Chapel Hill","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"FHI 360","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FHI 360 \/ Family Health Options Kenya | Gilead Sciences | Institute of Tropical Medicine | Sex Workers Outreach Programme | University of North Carolina, Chapel Hill","highestDevelopmentStatusID":"1","companyTruncated":"FHI 360 \/ Family Health Options Kenya | Gilead Sciences | Institute of Tropical Medicine | Sex Workers Outreach Programme | University of North Carolina, Chapel Hill"},{"orgOrder":0,"company":"James Egan","sponsor":"Fenway Community Health | National Institute of Mental Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"James Egan","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"James Egan \/ Fenway Community Health | National Institute of Mental Health","highestDevelopmentStatusID":"1","companyTruncated":"James Egan \/ Fenway Community Health | National Institute of Mental Health"},{"orgOrder":0,"company":"University of Southern California","sponsor":"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Etravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Southern California","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Southern California \/ Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA","highestDevelopmentStatusID":"1","companyTruncated":"University of Southern California \/ Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA"},{"orgOrder":0,"company":"Valme University Hospital","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Nevirapine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valme University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valme University Hospital \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Valme University Hospital \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"University of Hong Kong","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Hong Kong","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Hong Kong \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"University of Hong Kong \/ Gilead Sciences"},{"orgOrder":0,"company":"ANRS, Emerging Infectious Diseases","sponsor":"Africa Centre For Health and Population Studies | University of KwaZulu","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ANRS, Emerging Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANRS, Emerging Infectious Diseases \/ Africa Centre For Health and Population Studies | University of KwaZulu","highestDevelopmentStatusID":"1","companyTruncated":"ANRS, Emerging Infectious Diseases \/ Africa Centre For Health and Population Studies | University of KwaZulu"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"University of Washington","sponsor":"Clinique des Maladies Infectieuses, Fann | Centre de Sant\u00e9 de Ziguinchor | Johnson & Johnson Innovative Medicine | Merck & Co | National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Zidovudine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Clinique des Maladies Infectieuses, Fann | Centre de Sant\u00e9 de Ziguinchor | Johnson & Johnson Innovative Medicine | Merck & Co | National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"1","companyTruncated":"University of Washington \/ Clinique des Maladies Infectieuses, Fann | Centre de Sant\u00e9 de Ziguinchor | Johnson & Johnson Innovative Medicine | Merck & Co | National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Inflammasome Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Inflammasome Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Inflammasome Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Amarillo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interferon Alpha","moa":"IFNAR","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Amarillo Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarillo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Amarillo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NellOne Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NELL1","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NellOne Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NellOne Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NellOne Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Composite Interceptive Med Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Polyherbal","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Composite Interceptive Med Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Composite Interceptive Med Science \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Composite Interceptive Med Science \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Universiti Sains Malaysia","sponsor":"Beijing Scitop Bio-Tech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MALAYSIA","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Universiti Sains Malaysia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universiti Sains Malaysia \/ Beijing Scitop Bio-Tech Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Universiti Sains Malaysia \/ Beijing Scitop Bio-Tech Co., Ltd."},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"The Danish Council for Strategic Research | Chr. Hansen | Technical University of Denmark | University of Bergen | Odense University Hospital | Statens Serum Institut","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ The Danish Council for Strategic Research | Chr. Hansen | Technical University of Denmark | University of Bergen | Odense University Hospital | Statens Serum Institut","highestDevelopmentStatusID":"1","companyTruncated":"University of Copenhagen \/ The Danish Council for Strategic Research | Chr. Hansen | Technical University of Denmark | University of Bergen | Odense University Hospital | Statens Serum Institut"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"The Danish Council for Strategic Research | Chr. Hansen | Technical University of Denmark | University of Bergen | Odense University Hospital | Statens Serum Institut","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ The Danish Council for Strategic Research | Chr. Hansen | Technical University of Denmark | University of Bergen | Odense University Hospital | Statens Serum Institut","highestDevelopmentStatusID":"1","companyTruncated":"University of Copenhagen \/ The Danish Council for Strategic Research | Chr. Hansen | Technical University of Denmark | University of Bergen | Odense University Hospital | Statens Serum Institut"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kerry Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kerry Group \/ Undisclosed"},{"orgOrder":0,"company":"NIZO Food Research","sponsor":"Danisco","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NIZO Food Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIZO Food Research \/ Danisco","highestDevelopmentStatusID":"1","companyTruncated":"NIZO Food Research \/ Danisco"},{"orgOrder":0,"company":"NIZO Food Research","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NIZO Food Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIZO Food Research \/ Lallemand Health Solutions","highestDevelopmentStatusID":"1","companyTruncated":"NIZO Food Research \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"Medical University of Warsaw","sponsor":"Miralex Sp. z o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medical University of Warsaw","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of Warsaw \/ Miralex Sp. z o.o.","highestDevelopmentStatusID":"1","companyTruncated":"Medical University of Warsaw \/ Miralex Sp. z o.o."},{"orgOrder":0,"company":"Nordic Biotic Sp. z o.o.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nordic Biotic Sp. z o.o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Biotic Sp. z o.o. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nordic Biotic Sp. z o.o. \/ Undisclosed"},{"orgOrder":0,"company":"Bioithas SL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bioithas SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bioithas SL \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bioithas SL \/ Undisclosed"},{"orgOrder":0,"company":"AB Biotics","sponsor":"Germans Trias i Pujol Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AB Biotics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Biotics \/ Germans Trias i Pujol Hospital","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotics \/ Germans Trias i Pujol Hospital"},{"orgOrder":0,"company":"AB Biotics","sponsor":"Innovacion y Desarrollo de Estrategias en Salud | Hospital General Dr. Manuel Gea Gonz\u00e1lez","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AB Biotics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Biotics \/ Innovacion y Desarrollo de Estrategias en Salud | Hospital General Dr. Manuel Gea Gonz\u00e1lez","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotics \/ Innovacion y Desarrollo de Estrategias en Salud | Hospital General Dr. Manuel Gea Gonz\u00e1lez"},{"orgOrder":0,"company":"ProbiSearch SL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ProbiSearch SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProbiSearch SL \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ProbiSearch SL \/ Undisclosed"},{"orgOrder":0,"company":"Region Skane","sponsor":"Probi AB","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Region Skane","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Region Skane \/ Probi AB","highestDevelopmentStatusID":"1","companyTruncated":"Region Skane \/ Probi AB"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IBSS BIOMED","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"IBSS BIOMED","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSS BIOMED \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"IBSS BIOMED \/ Undisclosed"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"Onorach Clinical | CPS Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ Onorach Clinical | CPS Research","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ Onorach Clinical | CPS Research"},{"orgOrder":0,"company":"Sprim Advanced Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sprim Advanced Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sprim Advanced Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sprim Advanced Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke \/ Lallemand Health Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke \/ Lallemand Health Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"Nutrition 21, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nutrition 21, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrition 21, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutrition 21, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"University of Medicine and Dentistry of New Jersey","sponsor":"Chr. Hansen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Medicine and Dentistry of New Jersey","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Medicine and Dentistry of New Jersey \/ Chr. Hansen","highestDevelopmentStatusID":"1","companyTruncated":"University of Medicine and Dentistry of New Jersey \/ Chr. Hansen"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Danisco","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ Danisco","highestDevelopmentStatusID":"1","companyTruncated":"University of Wisconsin, Madison \/ Danisco"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Vedic Lifesciences Pvt. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Archer Daniels Midland \/ Vedic Lifesciences Pvt. Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Vedic Lifesciences Pvt. Ltd."},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Archer Daniels Midland \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"Farmoquimica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Farmoquimica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Farmoquimica \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Farmoquimica \/ Undisclosed"},{"orgOrder":0,"company":"Min-Tze LIONG","sponsor":"International Islamic University Malaysia | Beijing Scitop Bio-Tech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Min-Tze LIONG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Min-Tze LIONG \/ International Islamic University Malaysia | Beijing Scitop Bio-Tech Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Min-Tze LIONG \/ International Islamic University Malaysia | Beijing Scitop Bio-Tech Co., Ltd."},{"orgOrder":0,"company":"GenMont Biotech Incorporation","sponsor":"Kuo General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GenMont Biotech Incorporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenMont Biotech Incorporation \/ Kuo General Hospital","highestDevelopmentStatusID":"1","companyTruncated":"GenMont Biotech Incorporation \/ Kuo General Hospital"},{"orgOrder":0,"company":"Innovacion y Desarrollo de Estrategias en Salud","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Innovacion y Desarrollo de Estrategias en Salud","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovacion y Desarrollo de Estrategias en Salud \/ BioGaia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Innovacion y Desarrollo de Estrategias en Salud \/ BioGaia Pharma"},{"orgOrder":0,"company":"Lesaffre International","sponsor":"Eurofins CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Saccharomyces Cerevisiae","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lesaffre International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lesaffre International \/ Eurofins CDMO","highestDevelopmentStatusID":"1","companyTruncated":"Lesaffre International \/ Eurofins CDMO"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Fougera Pharmaceuticals Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sinecatechins","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Fougera Pharmaceuticals Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Fougera Pharmaceuticals Inc."},{"orgOrder":0,"company":"Biolab Sanus Farmaceutica","sponsor":"Medcin Instituto da Pele","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Stryphnodendron Adstringens Extract","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biolab Sanus Farmaceutica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolab Sanus Farmaceutica \/ Medcin Instituto da Pele","highestDevelopmentStatusID":"1","companyTruncated":"Biolab Sanus Farmaceutica \/ Medcin Instituto da Pele"},{"orgOrder":0,"company":"Swissx Labs AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Naja Venom","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Swissx Labs AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swissx Labs AG \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Swissx Labs AG \/ Undisclosed"},{"orgOrder":0,"company":"ViralClear Pharmaceuticals","sponsor":"Neuroclear","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Merimepodib","moa":"Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ViralClear Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"ViralClear Pharmaceuticals \/ Neuroclear","highestDevelopmentStatusID":"1","companyTruncated":"ViralClear Pharmaceuticals \/ Neuroclear"},{"orgOrder":0,"company":"Henan Provincial People's Hospital","sponsor":"Xiamen Amoytop Biotech Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Henan Provincial People's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Henan Provincial People's Hospital \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Henan Provincial People's Hospital \/ Xiamen Amoytop Biotech Co., Ltd"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Taiwan University Hospital \/ PharmaEssentia","highestDevelopmentStatusID":"1","companyTruncated":"National Taiwan University Hospital \/ PharmaEssentia"},{"orgOrder":0,"company":"Columbia University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Interferon Alpha-2a","moa":"Interferon alpha\/beta receptor 1; Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Merck & Co"},{"orgOrder":0,"company":"SPP Pharmaclon Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Polyferon","moa":"Interferon gamma receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SPP Pharmaclon Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SPP Pharmaclon Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"SPP Pharmaclon Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Lakehead University","sponsor":"Thunder Bay Regional Health Sciences Centre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Iodine Povacrylex","moa":"iodine-containing contrast media","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lakehead University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lakehead University \/ Thunder Bay Regional Health Sciences Centre","highestDevelopmentStatusID":"1","companyTruncated":"Lakehead University \/ Thunder Bay Regional Health Sciences Centre"},{"orgOrder":0,"company":"Terra Biological","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Oxaloacetate","moa":"Krebs cycle","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Terra Biological","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terra Biological \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Terra Biological \/ Undisclosed"},{"orgOrder":0,"company":"Kalos Therapeutics","sponsor":"Oncology Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"KTH-222","moa":"MAPK","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kalos Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kalos Therapeutics \/ Oncology Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Kalos Therapeutics \/ Oncology Pharmaceuticals"},{"orgOrder":0,"company":"Kalos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"KTH-222","moa":"MAPK","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kalos Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kalos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kalos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"ZonMw | Academisch Medisch Centrum - Universiteit van Amsterdam | University College, London","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Radboud University Medical Center \/ ZonMw | Academisch Medisch Centrum - Universiteit van Amsterdam | University College, London","highestDevelopmentStatusID":"1","companyTruncated":"Radboud University Medical Center \/ ZonMw | Academisch Medisch Centrum - Universiteit van Amsterdam | University College, London"},{"orgOrder":0,"company":"Medical Corps, Israel Defense Force","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medical Corps, Israel Defense Force","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical Corps, Israel Defense Force \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Medical Corps, Israel Defense Force \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"||Melatonin receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Undisclosed"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Hope Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"HB-adMSC","moa":"Mesenchymal stem cells","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hope Biosciences \/ Hope Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Hope Biosciences \/ Hope Biosciences"},{"orgOrder":0,"company":"Comenius University","sponsor":"Kaneka Pharma Europe N.V. | Sanat\u00f3rium of Dr. Guhr, n.o.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SLOVAKIA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Comenius University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Comenius University \/ Kaneka Pharma Europe N.V. | Sanat\u00f3rium of Dr. Guhr, n.o.","highestDevelopmentStatusID":"1","companyTruncated":"Comenius University \/ Kaneka Pharma Europe N.V. | Sanat\u00f3rium of Dr. Guhr, n.o."},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IC14","moa":"Monocyte differentiation antigen CD14","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Implicit Bioscience \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Implicit Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IC14","moa":"Monocyte differentiation antigen CD14","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Implicit Bioscience \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Implicit Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Reading Scientific Services","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Partnership","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Reading Scientific Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reading Scientific Services \/ Ethypharm","highestDevelopmentStatusID":"1","companyTruncated":"Reading Scientific Services \/ Ethypharm"},{"orgOrder":0,"company":"Montefiore Medical Center","sponsor":"Westat | Massachusetts General Hospital | Truth Initiative | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Montefiore Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Montefiore Medical Center \/ Westat | Massachusetts General Hospital | Truth Initiative | National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"Montefiore Medical Center \/ Westat | Massachusetts General Hospital | Truth Initiative | National Cancer Institute"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Quadramune","moa":"NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Guaifenesin","moa":"NMDA receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Albert Einstein Healthcare Network","sponsor":"Emergency Medicine Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Albert Einstein Healthcare Network","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albert Einstein Healthcare Network \/ Emergency Medicine Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Albert Einstein Healthcare Network \/ Emergency Medicine Foundation"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Daclatasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Daclatasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Timothy Morgan, MD","sponsor":"VA Long Beach Healthcare System | National Cancer Institute | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Daclatasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Timothy Morgan, MD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Timothy Morgan, MD \/ VA Long Beach Healthcare System | National Cancer Institute | Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Timothy Morgan, MD \/ VA Long Beach Healthcare System | National Cancer Institute | Bristol Myers Squibb"},{"orgOrder":0,"company":"Hospital de Clinicas de Porto Alegre","sponsor":"Ministry of Health, Brazil | State Secretary of Health of Rio Grande do Sul | Telessa\u00fadeRS \/ UFRGS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Velpatasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hospital de Clinicas de Porto Alegre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital de Clinicas de Porto Alegre \/ Ministry of Health, Brazil | State Secretary of Health of Rio Grande do Sul | Telessa\u00fadeRS \/ UFRGS","highestDevelopmentStatusID":"1","companyTruncated":"Hospital de Clinicas de Porto Alegre \/ Ministry of Health, Brazil | State Secretary of Health of Rio Grande do Sul | Telessa\u00fadeRS \/ UFRGS"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"INSERM | Versailles Saint Quentin en Yvelines University | Universit\u00e9 Paris-Saclay | Paris 12 Val de Marne University | Commissariat A L'energie Atomique | Beckman Coulter | Lumedix | Elice | Biothelis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"NR3C1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ INSERM | Versailles Saint Quentin en Yvelines University | Universit\u00e9 Paris-Saclay | Paris 12 Val de Marne University | Commissariat A L'energie Atomique | Beckman Coulter | Lumedix | Elice | Biothelis","highestDevelopmentStatusID":"1","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ INSERM | Versailles Saint Quentin en Yvelines University | Universit\u00e9 Paris-Saclay | Paris 12 Val de Marne University | Commissariat A L'energie Atomique | Beckman Coulter | Lumedix | Elice | Biothelis"},{"orgOrder":0,"company":"Macfarlane Burnet Institute for Medical Research and Public Health Ltd","sponsor":"Health Poverty Action | Centre of Malariology Parasitology and Entomology, Department of Communicable Diseases Control, Ministry of Health, Lao PDR | National Centre for Parasitology, Entomology and Malaria Control, Cambodia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Icaridin","moa":"Odorant binding protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Macfarlane Burnet Institute for Medical Research and Public Health Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Macfarlane Burnet Institute for Medical Research and Public Health Ltd \/ Health Poverty Action | Centre of Malariology Parasitology and Entomology, Department of Communicable Diseases Control, Ministry of Health, Lao PDR | National Centre for Parasitology, Entomology and Malaria Control, Cambodia","highestDevelopmentStatusID":"1","companyTruncated":"Macfarlane Burnet Institute for Medical Research and Public Health Ltd \/ Health Poverty Action | Centre of Malariology Parasitology and Entomology, Department of Communicable Diseases Control, Ministry of Health, Lao PDR | National Centre for Parasitology, Entomology and Malaria Control, Cambodia"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Erdosteine","moa":"Pancreatic elastase 1 (CELA1)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Recipharm AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recipharm AB \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Recipharm AB \/ Undisclosed"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Qatar University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"QATAR","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Qatar University","highestDevelopmentStatusID":"1","companyTruncated":"Hamad Medical Corporation \/ Qatar University"},{"orgOrder":0,"company":"Christiana Care Health Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Christiana Care Health Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Christiana Care Health Services \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Christiana Care Health Services \/ Undisclosed"},{"orgOrder":0,"company":"McMaster University","sponsor":"Physician Services Incorporated | Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McMaster University \/ Physician Services Incorporated | Canadian Institutes of Health Research","highestDevelopmentStatusID":"1","companyTruncated":"McMaster University \/ Physician Services Incorporated | Canadian Institutes of Health Research"},{"orgOrder":0,"company":"W.J. Wiersinga, MD, PhD","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"W.J. Wiersinga, MD, PhD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"W.J. Wiersinga, MD, PhD \/ ZonMw","highestDevelopmentStatusID":"1","companyTruncated":"W.J. Wiersinga, MD, PhD \/ ZonMw"},{"orgOrder":0,"company":"Profounda Pharmaceuticals","sponsor":"Knight Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Miltefosine","moa":"phosphoro-derivatives","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Profounda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Profounda Pharmaceuticals \/ Knight Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Profounda Pharmaceuticals \/ Knight Therapeutics"},{"orgOrder":0,"company":"Vedic Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"5-aminolevulinic Acid Phosphate","moa":"Photosensitiser","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vedic Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedic Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vedic Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Aviron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Aprotinin","moa":"Plasma kallikrein | Plasminogen","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aviron","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aviron \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Aviron \/ Undisclosed"},{"orgOrder":0,"company":"Menzies School of Health Research","sponsor":"Walter and Eliza Hall Institute | Ministry of Health, Vanuatu | Ministry of Health, Solomon Islands | World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Primaquine Diphosphate","moa":"Plasmodium Deoxyribonucleic acid (Malaria DNA)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Menzies School of Health Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Menzies School of Health Research \/ Walter and Eliza Hall Institute | Ministry of Health, Vanuatu | Ministry of Health, Solomon Islands | World Health Organization","highestDevelopmentStatusID":"1","companyTruncated":"Menzies School of Health Research \/ Walter and Eliza Hall Institute | Ministry of Health, Vanuatu | Ministry of Health, Solomon Islands | World Health Organization"},{"orgOrder":0,"company":"PATH","sponsor":"Ministry of Health, Zambia | Minister of Community Development, Mother and Child Health, Zambia | Tulane University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Piperaquine Tetraphosphate","moa":"Plasmodium falciparum","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PATH","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PATH \/ Ministry of Health, Zambia | Minister of Community Development, Mother and Child Health, Zambia | Tulane University","highestDevelopmentStatusID":"1","companyTruncated":"PATH \/ Ministry of Health, Zambia | Minister of Community Development, Mother and Child Health, Zambia | Tulane University"},{"orgOrder":0,"company":"Slovenian Society for Gastroenterology and Hepatology","sponsor":"Krka","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SLOVENIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Slovenian Society for Gastroenterology and Hepatology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Slovenian Society for Gastroenterology and Hepatology \/ Krka","highestDevelopmentStatusID":"1","companyTruncated":"Slovenian Society for Gastroenterology and Hepatology \/ Krka"},{"orgOrder":0,"company":"Zagazig University","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"EGYPT","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zagazig University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zagazig University \/ BioGaia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Zagazig University \/ BioGaia Pharma"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"SK Chemicals | Chong Kun Dang Pharm | HK inno.N | Green Cross Lab Cell","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Bundang Hospital \/ SK Chemicals | Chong Kun Dang Pharm | HK inno.N | Green Cross Lab Cell","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Bundang Hospital \/ SK Chemicals | Chong Kun Dang Pharm | HK inno.N | Green Cross Lab Cell"},{"orgOrder":0,"company":"FHI 360","sponsor":"University of Washington | Wits Reproductive Health and HIV Institute | World Health Organization | Madibeng Centre for Research | Maternal Adolescent and Child Health Research | Qhakaza Mbokodo Research Clinic | The Aurum Institute NPC | Effective Care R","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Hormone","year":"2015","type":"Inapplicable","leadProduct":"Medroxyprogesterone Acetate","moa":"Progesterone receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"FHI 360","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"FHI 360 \/ University of Washington | Wits Reproductive Health and HIV Institute | World Health Organization | Madibeng Centre for Research | Maternal Adolescent and Child Health Research | Qhakaza Mbokodo Research Clinic | The Aurum Institute NPC | Effective Care R","highestDevelopmentStatusID":"1","companyTruncated":"FHI 360 \/ University of Washington | Wits Reproductive Health and HIV Institute | World Health Organization | Madibeng Centre for Research | Maternal Adolescent and Child Health Research | Qhakaza Mbokodo Research Clinic | The Aurum Institute NPC | Effective Care R"},{"orgOrder":0,"company":"SIRS Therapeutics","sponsor":"Wellington Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Financing","leadProduct":"FX06","moa":"Pro-inflammatory fibrin E1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SIRS Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIRS Therapeutics \/ Wellington Partners","highestDevelopmentStatusID":"1","companyTruncated":"SIRS Therapeutics \/ Wellington Partners"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"National Liver Institute, Egypt | Cairo University | High Institute of Public Health, Egypt","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Arachidonic Acid","moa":"Prostaglandin G\/H synthase 1 (COX-1)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"Royal DSM \/ National Liver Institute, Egypt | Cairo University | High Institute of Public Health, Egypt","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ National Liver Institute, Egypt | Cairo University | High Institute of Public Health, Egypt"},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"Innovation Fund Denmark","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"HPAPI","year":"2020","type":"Funding","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigshospitalet \/ Innovation Fund Denmark","highestDevelopmentStatusID":"1","companyTruncated":"Rigshospitalet \/ Innovation Fund Denmark"},{"orgOrder":0,"company":"Dimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Propagermanium","moa":"quaternary ammonium derivatives","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dimerix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dimerix \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Dimerix \/ Undisclosed"},{"orgOrder":0,"company":"Mahidol University","sponsor":"VINS Bioproducts Ltd. | Biogentech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Equine Rabies Immunoglobulin","moa":"Rabies virus","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mahidol University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mahidol University \/ VINS Bioproducts Ltd. | Biogentech","highestDevelopmentStatusID":"1","companyTruncated":"Mahidol University \/ VINS Bioproducts Ltd. | Biogentech"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Continuous Renal Replacement Therapy","moa":"Renal replacement","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Henan Genuine Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azvudine","moa":"Replicase polyprotein 1ab | Reverse transcriptase | Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Henan Genuine Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Henan Genuine Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Henan Genuine Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Ruijin Hospital","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tenofovir Amibufenamide","moa":"Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ruijin Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ruijin Hospital \/ Hansoh Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Ruijin Hospital \/ Hansoh Pharma"},{"orgOrder":0,"company":"University of Virginia","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2012","type":"Inapplicable","leadProduct":"Rhinovirus","moa":"Rhinovirus","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Virginia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Virginia \/ International Flavors and Fragrances","highestDevelopmentStatusID":"1","companyTruncated":"University of Virginia \/ International Flavors and Fragrances"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Analyze & Realize"},{"orgOrder":0,"company":"Institute of Chemical Technology","sponsor":"Lasa Supergenerics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute of Chemical Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Institute of Chemical Technology \/ Lasa Supergenerics","highestDevelopmentStatusID":"1","companyTruncated":"Institute of Chemical Technology \/ Lasa Supergenerics"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sihuan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sihuan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Brinton Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Brinton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Brinton Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Brinton Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"NICHD","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-directed RNA polymerase L | Replicase polyprotein 1ab","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ NICHD","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ NICHD"},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 mRNA Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Precision NanoSystems","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Precision NanoSystems \/ Government of Canada","highestDevelopmentStatusID":"1","companyTruncated":"Precision NanoSystems \/ Government of Canada"},{"orgOrder":0,"company":"Chinese Academy of Sciences","sponsor":"Zhifei Longcom Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chinese Academy of Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese Academy of Sciences \/ Zhifei Longcom Biopharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Chinese Academy of Sciences \/ Zhifei Longcom Biopharmaceutical"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"VLP Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"||SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujifilm holding \/ VLP Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Fujifilm holding \/ VLP Therapeutics"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Themis Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ Themis Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"ABL Bio \/ Themis Bioscience"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Adimmune","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Eden Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eden Biologics \/ Adimmune","highestDevelopmentStatusID":"1","companyTruncated":"Eden Biologics \/ Adimmune"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"SK Bioscience \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medigen Vaccine Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigen Vaccine Biologics \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Medigen Vaccine Biologics \/ National Institutes of Health"},{"orgOrder":0,"company":"Mynvax","sponsor":"Indian Institute of Science","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mynvax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mynvax \/ Indian Institute of Science","highestDevelopmentStatusID":"1","companyTruncated":"Mynvax \/ Indian Institute of Science"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Pasteur \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ CEPI"},{"orgOrder":0,"company":"Coalition for Epidemic Preparedness Innovations","sponsor":"UK Governement","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Coalition for Epidemic Preparedness Innovations","amount2":0.27000000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.27000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Coalition for Epidemic Preparedness Innovations \/ UK Governement","highestDevelopmentStatusID":"1","companyTruncated":"Coalition for Epidemic Preparedness Innovations \/ UK Governement"},{"orgOrder":0,"company":"Sechenov University Center for Clinical Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sechenov University Center for Clinical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sechenov University Center for Clinical Research \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sechenov University Center for Clinical Research \/ Undisclosed"},{"orgOrder":0,"company":"Russian Defence Ministry","sponsor":"National Research Center For Epidemiology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Russian Defence Ministry","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Russian Defence Ministry \/ National Research Center For Epidemiology","highestDevelopmentStatusID":"1","companyTruncated":"Russian Defence Ministry \/ National Research Center For Epidemiology"},{"orgOrder":0,"company":"AJ Vaccines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AJ Vaccines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AJ Vaccines \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AJ Vaccines \/ Undisclosed"},{"orgOrder":0,"company":"ExpreS2ion Biotechnologies","sponsor":"The EU Horizon 2020 Consortium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ExpreS2ion Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExpreS2ion Biotechnologies \/ The EU Horizon 2020 Consortium","highestDevelopmentStatusID":"1","companyTruncated":"ExpreS2ion Biotechnologies \/ The EU Horizon 2020 Consortium"},{"orgOrder":0,"company":"Exyte","sponsor":"Univercells","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exyte","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exyte \/ Univercells","highestDevelopmentStatusID":"1","companyTruncated":"Exyte \/ Univercells"},{"orgOrder":0,"company":"Celonic","sponsor":"Intravacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celonic \/ Intravacc","highestDevelopmentStatusID":"1","companyTruncated":"Celonic \/ Intravacc"},{"orgOrder":0,"company":"Neovii","sponsor":"Tel Aviv University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Neovii","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neovii \/ Tel Aviv University","highestDevelopmentStatusID":"1","companyTruncated":"Neovii \/ Tel Aviv University"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Barinthus Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"AstraZeneca \/ Barinthus Biotherapeutics"},{"orgOrder":0,"company":"Vibalogics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vibalogics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vibalogics \/ Johnson & Johnson","highestDevelopmentStatusID":"1","companyTruncated":"Vibalogics \/ Johnson & Johnson"},{"orgOrder":0,"company":"MigVax","sponsor":"Ourcrowd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"MigVax","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"MigVax \/ Ourcrowd","highestDevelopmentStatusID":"1","companyTruncated":"MigVax \/ Ourcrowd"},{"orgOrder":0,"company":"Tulane University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tulane University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tulane University \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tulane University \/ Undisclosed"},{"orgOrder":0,"company":"Institute for Systems Biology","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute for Systems Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute for Systems Biology \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Institute for Systems Biology \/ Merck & Co"},{"orgOrder":0,"company":"Rochester Clinical Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rochester Clinical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rochester Clinical Research \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Rochester Clinical Research \/ Undisclosed"},{"orgOrder":0,"company":"Croda","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Croda","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Croda \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Croda \/ Pfizer Inc"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEL-SCI \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"CEL-SCI \/ Undisclosed"},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Beijing ZhonghuaInvestment Fund Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generex Biotechnology","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Generex Biotechnology \/ Beijing ZhonghuaInvestment Fund Management","highestDevelopmentStatusID":"1","companyTruncated":"Generex Biotechnology \/ Beijing ZhonghuaInvestment Fund Management"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"US Army Contracting Command","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.11,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Ology Bioservices \/ US Army Contracting Command","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ US Army Contracting Command"},{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"VIDO-InterVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dalton Pharma Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dalton Pharma Services \/ VIDO-InterVac","highestDevelopmentStatusID":"1","companyTruncated":"Dalton Pharma Services \/ VIDO-InterVac"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive Phage Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":1,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ BARDA"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Biological E","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Biological E","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Biological E"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"McKesson","sponsor":"Centers For Disease Control","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"McKesson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McKesson \/ Centers For Disease Control","highestDevelopmentStatusID":"1","companyTruncated":"McKesson \/ Centers For Disease Control"},{"orgOrder":0,"company":"Griffith University","sponsor":"Luina Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Griffith University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Griffith University \/ Luina Bio","highestDevelopmentStatusID":"1","companyTruncated":"Griffith University \/ Luina Bio"},{"orgOrder":0,"company":"The Peter Doherty Institute","sponsor":"Jack Ma Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Peter Doherty Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Peter Doherty Institute \/ Jack Ma Foundation","highestDevelopmentStatusID":"1","companyTruncated":"The Peter Doherty Institute \/ Jack Ma Foundation"},{"orgOrder":0,"company":"Public health and reforms Center of Ministry of Health","sponsor":"World Health Organization | Ministry of Health of Azerbaijan Republic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Public health and reforms Center of Ministry of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Public health and reforms Center of Ministry of Health \/ World Health Organization | Ministry of Health of Azerbaijan Republic","highestDevelopmentStatusID":"1","companyTruncated":"Public health and reforms Center of Ministry of Health \/ World Health Organization | Ministry of Health of Azerbaijan Republic"},{"orgOrder":0,"company":"COVAX Advance Market Commitment","sponsor":"Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"COVAX Advance Market Commitment","amount2":0.070000000000000007,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"COVAX Advance Market Commitment \/ Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"COVAX Advance Market Commitment \/ Gates Foundation"},{"orgOrder":0,"company":"World Health Organization","sponsor":"Governemnt of Mexico","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"World Health Organization","amount2":0.16,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"World Health Organization \/ Governemnt of Mexico","highestDevelopmentStatusID":"1","companyTruncated":"World Health Organization \/ Governemnt of Mexico"},{"orgOrder":0,"company":"World Health Organization","sponsor":"Japanese Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"World Health Organization","amount2":0.17000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.17000000000000001,"dosageForm":"Undisclosed","sponsorNew":"World Health Organization \/ Japanese Government","highestDevelopmentStatusID":"1","companyTruncated":"World Health Organization \/ Japanese Government"},{"orgOrder":0,"company":"Imperial College London","sponsor":"hVIVO | Royal Free Hospital NHS FT","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Virus","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ hVIVO | Royal Free Hospital NHS FT","highestDevelopmentStatusID":"1","companyTruncated":"Imperial College London \/ hVIVO | Royal Free Hospital NHS FT"},{"orgOrder":0,"company":"TrippBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TD213","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TrippBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TrippBio \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TrippBio \/ Undisclosed"},{"orgOrder":0,"company":"TrippBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TD213","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TrippBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TrippBio \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TrippBio \/ Undisclosed"},{"orgOrder":0,"company":"International Centre for Diarrhoeal Disease Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BANGLADESH","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"International Centre for Diarrhoeal Disease Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"International Centre for Diarrhoeal Disease Research \/ Bharat Biotech","highestDevelopmentStatusID":"1","companyTruncated":"International Centre for Diarrhoeal Disease Research \/ Bharat Biotech"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2021","type":"Licensing Agreement","leadProduct":"EDV","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnGeneIC \/ ImmunityBio","highestDevelopmentStatusID":"1","companyTruncated":"EnGeneIC \/ ImmunityBio"},{"orgOrder":0,"company":"Chumakov Federal Scientific Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chumakov Federal Scientific Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chumakov Federal Scientific Center \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chumakov Federal Scientific Center \/ Undisclosed"},{"orgOrder":0,"company":"NanoPass Technologies","sponsor":"YNC Medical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NanoPass Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanoPass Technologies \/ YNC Medical","highestDevelopmentStatusID":"1","companyTruncated":"NanoPass Technologies \/ YNC Medical"},{"orgOrder":0,"company":"Vaxess","sponsor":"National Science Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"mRNA-Based COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vaxess","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxess \/ National Science Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Vaxess \/ National Science Foundation"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SK Bioscience","amount2":0.14000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"Exelead","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exelead","amount2":0.78000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.78000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Exelead \/ Merck Group","highestDevelopmentStatusID":"1","companyTruncated":"Exelead \/ Merck Group"},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"LSP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2020","type":"Series B Financing","leadProduct":"SARS-CoV-2 mRNA Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"eTheRNA immunotherapies","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"eTheRNA immunotherapies \/ LSP","highestDevelopmentStatusID":"1","companyTruncated":"eTheRNA immunotherapies \/ LSP"},{"orgOrder":0,"company":"Proteona","sponsor":"Flinders University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Proteona","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proteona \/ Flinders University","highestDevelopmentStatusID":"1","companyTruncated":"Proteona \/ Flinders University"},{"orgOrder":0,"company":"NEC Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NEC Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NEC Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NEC Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Sinovac Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CpG 1018","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dynavax Technologies \/ Sinovac Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Technologies \/ Sinovac Biotech"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Kansas State University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"TNX-2300","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kansas State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kansas State University \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"1","companyTruncated":"Kansas State University \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nafamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Mucokinetica","sponsor":"Covistat","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Nafamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mucokinetica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mucokinetica \/ Covistat","highestDevelopmentStatusID":"1","companyTruncated":"Mucokinetica \/ Covistat"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Serine\/threonine protein phosphatase 2B catalytic subunit, alpha isoform","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurinia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Aurinia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"UCLA Jonsson Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Berzosertib","moa":"Serine-protein kinase ATR","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck Group \/ UCLA Jonsson Comprehensive Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"Merck Group \/ UCLA Jonsson Comprehensive Cancer Center"},{"orgOrder":0,"company":"Renmin Hospital of Wuhan University","sponsor":"Ansun Biopharm","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"DAS181","moa":"Sialoglycans | Glycosaminoglycans","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Renmin Hospital of Wuhan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Renmin Hospital of Wuhan University \/ Ansun Biopharm","highestDevelopmentStatusID":"1","companyTruncated":"Renmin Hospital of Wuhan University \/ Ansun Biopharm"},{"orgOrder":0,"company":"EngenderHealth","sponsor":"Weill Medical College of Cornell University | Bon Sante Consulting Limited | Kenya National AIDS & STI Control Programme | Kenya Ministry of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EngenderHealth","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EngenderHealth \/ Weill Medical College of Cornell University | Bon Sante Consulting Limited | Kenya National AIDS & STI Control Programme | Kenya Ministry of Health","highestDevelopmentStatusID":"1","companyTruncated":"EngenderHealth \/ Weill Medical College of Cornell University | Bon Sante Consulting Limited | Kenya National AIDS & STI Control Programme | Kenya Ministry of Health"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Imperial College London \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Imperial College London \/ Undisclosed"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bellerophon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Massachusetts General Hospital \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"VERO Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VERO Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"VERO Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"VERO Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Oystershell NV","sponsor":"Eurofins Dermscan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Amorolfine Hydrochloride","moa":"squalene","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oystershell NV","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oystershell NV \/ Eurofins Dermscan","highestDevelopmentStatusID":"1","companyTruncated":"Oystershell NV \/ Eurofins Dermscan"},{"orgOrder":0,"company":"AI VIVO","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Imatinib Mesylate","moa":"Stem cell growth factor receptor | Platelet-derived growth factor receptor beta | Bcr\/Abl fusion protein | Tyrosine-protein kinase ABL","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AI VIVO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AI VIVO \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AI VIVO \/ Undisclosed"},{"orgOrder":0,"company":"Exvastat","sponsor":"Innovative Medicines Initiative","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Imatinib Mesylate","moa":"Stem cell growth factor receptor | Platelet-derived growth factor receptor beta | Bcr\/Abl fusion protein | Tyrosine-protein kinase ABL","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exvastat","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exvastat \/ Innovative Medicines Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Exvastat \/ Innovative Medicines Initiative"},{"orgOrder":0,"company":"Corpometria Institute","sponsor":"Applied Biology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ECUADOR","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Dutasteride","moa":"||Steroid 5-alpha-reductase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Corpometria Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corpometria Institute \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Corpometria Institute \/ Applied Biology"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"diABZI","moa":"STING","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"University of Pennsylvania \/ Undisclosed"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Agence de M\u00e9decine Pr\u00e9ventive | Centre Muraz | INSERM | Gilead Sciences | Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine","moa":"Surface antigen (HBsAg)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Pasteur \/ Agence de M\u00e9decine Pr\u00e9ventive | Centre Muraz | INSERM | Gilead Sciences | Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ Agence de M\u00e9decine Pr\u00e9ventive | Centre Muraz | INSERM | Gilead Sciences | Abbott Laboratories"},{"orgOrder":0,"company":"University of Louisville","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine","moa":"Surface antigen (HBsAg)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Louisville","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Louisville \/ Dynavax Technologies","highestDevelopmentStatusID":"1","companyTruncated":"University of Louisville \/ Dynavax Technologies"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Public Offering","leadProduct":"CpG 1018","moa":"||Surface antigen (HBsAg)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0.080000000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Dynavax Technologies \/ Cowen","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Technologies \/ Cowen"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Valneva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CpG 1018","moa":"||Surface antigen (HBsAg)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dynavax Technologies \/ Valneva","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Technologies \/ Valneva"},{"orgOrder":0,"company":"Tel Aviv Sourasky Medical Center (Ichilov Hospital)","sponsor":"SciGen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine Recombinant","moa":"Surface antigen (HBsAg)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tel Aviv Sourasky Medical Center (Ichilov Hospital)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tel Aviv Sourasky Medical Center (Ichilov Hospital) \/ SciGen","highestDevelopmentStatusID":"1","companyTruncated":"Tel Aviv Sourasky Medical Center (Ichilov Hospital) \/ SciGen"},{"orgOrder":0,"company":"Soroka University Medical Center","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Soroka University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soroka University Medical Center \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"Soroka University Medical Center \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"CARE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Imiquimod","moa":"||Toll-like receptor 7","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CARE","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARE \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"CARE \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"||Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"University of Oxford \/ Undisclosed"},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Rising Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Minnesota \/ Rising Pharmaceuticals Inc","highestDevelopmentStatusID":"1","companyTruncated":"University of Minnesota \/ Rising Pharmaceuticals Inc"},{"orgOrder":0,"company":"Lupus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lupus Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lupus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Codebase","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Codebase","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codebase \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Codebase \/ Undisclosed"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PRTX007","moa":"Toll-like-7 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Primmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Primmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Meridian IT","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Partnership","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Meridian IT","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Meridian IT \/ Mateon Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Meridian IT \/ Mateon Therapeutics"},{"orgOrder":0,"company":"Canisius-Wilhelmina Hospital","sponsor":"Kappa Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Vitamin K2","moa":"Trypanosoma Cruzipain (Trypano CYSP)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Canisius-Wilhelmina Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canisius-Wilhelmina Hospital \/ Kappa Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"Canisius-Wilhelmina Hospital \/ Kappa Bioscience"},{"orgOrder":0,"company":"Inner Mongolia Yili Industrial Group Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Lactoferrin","moa":"Tryptase alpha\/beta-1 (Tryptase)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Inner Mongolia Yili Industrial Group Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inner Mongolia Yili Industrial Group Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Inner Mongolia Yili Industrial Group Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Xigo Health LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Lactoferrin","moa":"Tryptase alpha\/beta-1 (Tryptase)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Xigo Health LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xigo Health LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Xigo Health LLC \/ Undisclosed"},{"orgOrder":0,"company":"Hospices Civils de Lyon","sponsor":"Biomerieux","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Virus-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"TTV DNAemia","moa":"TTV DNAemia","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hospices Civils de Lyon","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospices Civils de Lyon \/ Biomerieux","highestDevelopmentStatusID":"1","companyTruncated":"Hospices Civils de Lyon \/ Biomerieux"},{"orgOrder":0,"company":"Shanghai Public Health Clinical Center","sponsor":"Kunming Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Shanghai Public Health Clinical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Public Health Clinical Center \/ Kunming Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Public Health Clinical Center \/ Kunming Pharmaceuticals"},{"orgOrder":0,"company":"Yale School of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"||Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Yale School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale School of Medicine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Yale School of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Indian Council of Medical Research \/ University of Oxford","highestDevelopmentStatusID":"1","companyTruncated":"Indian Council of Medical Research \/ University of Oxford"},{"orgOrder":0,"company":"Keck Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Keck Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keck Medicine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Keck Medicine \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Eli Lilly"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Austrian Research Promotion Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Carbohydrate","year":"2020","type":"Funding","leadProduct":"Carragelose","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Marinomed Biotech \/ Austrian Research Promotion Agency","highestDevelopmentStatusID":"1","companyTruncated":"Marinomed Biotech \/ Austrian Research Promotion Agency"},{"orgOrder":0,"company":"Entera Health","sponsor":"Lemus Buhils, SL | Clinical Research Unit, IMIM","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bovine Plasma-Derived Immunoglobulin Concentrate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Entera Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entera Health \/ Lemus Buhils, SL | Clinical Research Unit, IMIM","highestDevelopmentStatusID":"1","companyTruncated":"Entera Health \/ Lemus Buhils, SL | Clinical Research Unit, IMIM"},{"orgOrder":0,"company":"Shanghai BDgene","sponsor":"Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BD111","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Shanghai BDgene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai BDgene \/ Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai BDgene \/ Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"University of North Carolina | MedImmune","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"Influenza Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ University of North Carolina | MedImmune","highestDevelopmentStatusID":"1","companyTruncated":"University of North Carolina \/ University of North Carolina | MedImmune"},{"orgOrder":0,"company":"Vedic Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Doctor\\'S Biome Medical Food","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vedic Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedic Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vedic Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Vedic Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Paractin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vedic Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedic Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vedic Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Vedic Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Propionibacterium Freudenreichii P.UF1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vedic Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedic Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vedic Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"BravoVax","sponsor":"GeoVax Labs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"2019-nCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BravoVax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BravoVax \/ GeoVax Labs","highestDevelopmentStatusID":"1","companyTruncated":"BravoVax \/ GeoVax Labs"},{"orgOrder":0,"company":"Pasteur Institute","sponsor":"Vingroup Innovation Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"2019-nCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pasteur Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasteur Institute \/ Vingroup Innovation Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Pasteur Institute \/ Vingroup Innovation Foundation"},{"orgOrder":0,"company":"GSK","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"2019-nCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":"GSK \/ CEPI"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"2019-nCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"9-Valent HPV Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Weill Cornell Medicine","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Weill Cornell Medicine \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"1","companyTruncated":"Weill Cornell Medicine \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"AB Biotek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"ABBC1 Immunoessential","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AB Biotek","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"AB Biotek \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotek \/ Undisclosed"},{"orgOrder":0,"company":"AB Biotics","sponsor":"Cl\u00ednica Odontol\u00f3gica Nart en Barcelona","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Ab-Dentalac","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AB Biotics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Biotics \/ Cl\u00ednica Odontol\u00f3gica Nart en Barcelona","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotics \/ Cl\u00ednica Odontol\u00f3gica Nart en Barcelona"},{"orgOrder":0,"company":"University of Florida","sponsor":"Schwabe North America","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Acidophilus Pearls","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Florida \/ Schwabe North America","highestDevelopmentStatusID":"1","companyTruncated":"University of Florida \/ Schwabe North America"},{"orgOrder":0,"company":"Seagull Biosolutions","sponsor":"The Union Science and Technology Ministry of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Active Virosome Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Seagull Biosolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seagull Biosolutions \/ The Union Science and Technology Ministry of India","highestDevelopmentStatusID":"1","companyTruncated":"Seagull Biosolutions \/ The Union Science and Technology Ministry of India"},{"orgOrder":0,"company":"ReiThera","sponsor":"Univercells","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Adenoviral Vector-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ReiThera","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReiThera \/ Univercells","highestDevelopmentStatusID":"1","companyTruncated":"ReiThera \/ Univercells"},{"orgOrder":0,"company":"University of Washington","sponsor":"Standard Homeopathic Company","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Allium Cepa","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Standard Homeopathic Company","highestDevelopmentStatusID":"1","companyTruncated":"University of Washington \/ Standard Homeopathic Company"},{"orgOrder":0,"company":"Capricor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Cardiosphere-Derived Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Capricor","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Capricor \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Capricor \/ Undisclosed"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Cardiosphere-derived Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Capricor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Capricor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Alpha-Lactalbumin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AronPharma Sp. z o. o.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"AP203","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AronPharma Sp. z o. o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AronPharma Sp. z o. o. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AronPharma Sp. z o. o. \/ Undisclosed"},{"orgOrder":0,"company":"Composite Interceptive Med Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Arsenicum Album","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Composite Interceptive Med Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Composite Interceptive Med Science \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Composite Interceptive Med Science \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Xiamen Innovax Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"AS03","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Xiamen Innovax Biotech","highestDevelopmentStatusID":"1","companyTruncated":"GSK \/ Xiamen Innovax Biotech"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Aterixen","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"PiLeJe","sponsor":"Clinact | Clinfile","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Babybiane Imedia","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PiLeJe","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PiLeJe \/ Clinact | Clinfile","highestDevelopmentStatusID":"1","companyTruncated":"PiLeJe \/ Clinact | Clinfile"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Babyguard Breast Milk Probiotic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"DreamTec Research","sponsor":"DreamTec Cytokine Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Bacillus Subtilis Spore Extract","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DreamTec Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DreamTec Research \/ DreamTec Cytokine Limited","highestDevelopmentStatusID":"1","companyTruncated":"DreamTec Research \/ DreamTec Cytokine Limited"},{"orgOrder":0,"company":"Novozymes","sponsor":"Estimates OY","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Bacillus Velezensis DSM 33864","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novozymes \/ Estimates OY","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Estimates OY"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Serum Institute of India \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Serum Institute of India \/ Undisclosed"},{"orgOrder":0,"company":"University of Exeter Medical School","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Exeter Medical School","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Exeter Medical School \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"University of Exeter Medical School \/ Undisclosed"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Murdoch Children\u2019s Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Murdoch Children\u2019s Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Murdoch Children\u2019s Research Institute \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Murdoch Children\u2019s Research Institute \/ Undisclosed"},{"orgOrder":0,"company":"Fisabio","sponsor":"Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz | Hospital Universitario General de Villalba | Hospital Universitario Infanta Elena | Hospital Universitario Virgen de la Arrixaca | Hospital Cl\u00ednico Universitario de Valencia | Dentaid","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fisabio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fisabio \/ Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz | Hospital Universitario General de Villalba | Hospital Universitario Infanta Elena | Hospital Universitario Virgen de la Arrixaca | Hospital Cl\u00ednico Universitario de Valencia | Dentaid","highestDevelopmentStatusID":"1","companyTruncated":"Fisabio \/ Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz | Hospital Universitario General de Villalba | Hospital Universitario Infanta Elena | Hospital Universitario Virgen de la Arrixaca | Hospital Cl\u00ednico Universitario de Valencia | Dentaid"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Al-Azhar University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Al-Azhar University","highestDevelopmentStatusID":"1","companyTruncated":"Egymedicalpedia \/ Al-Azhar University"},{"orgOrder":0,"company":"University of Virginia","sponsor":"Danisco Sweeteners Oy","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Bifidobacterium Animalis Subsp. Lactis Bl-04","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Virginia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Virginia \/ Danisco Sweeteners Oy","highestDevelopmentStatusID":"1","companyTruncated":"University of Virginia \/ Danisco Sweeteners Oy"},{"orgOrder":0,"company":"Zagazig University","sponsor":"Charles Drew University of Medicine and Science | University of California, Irvine | Daiwa Pharmaceutical Corporation Co, Ltd, Tokyo 154-0024 Japan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"EGYPT","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Biobran","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zagazig University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zagazig University \/ Charles Drew University of Medicine and Science | University of California, Irvine | Daiwa Pharmaceutical Corporation Co, Ltd, Tokyo 154-0024 Japan","highestDevelopmentStatusID":"1","companyTruncated":"Zagazig University \/ Charles Drew University of Medicine and Science | University of California, Irvine | Daiwa Pharmaceutical Corporation Co, Ltd, Tokyo 154-0024 Japan"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Biogaia Protectis","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Love Wellness","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Boric Acid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Love Wellness","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Love Wellness \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Love Wellness \/ Citruslabs"},{"orgOrder":0,"company":"Al Adan Hospital Kuwait","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"KUWAIT","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Breastmilk","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Al Adan Hospital Kuwait","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Swab","sponsorNew":"Al Adan Hospital Kuwait \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Al Adan Hospital Kuwait \/ Undisclosed"},{"orgOrder":0,"company":"Second Affiliated Hospital of Wenzhou Medical University","sponsor":"WanBangDe Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Bromhexine Hydrochloride","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Second Affiliated Hospital of Wenzhou Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Second Affiliated Hospital of Wenzhou Medical University \/ WanBangDe Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Second Affiliated Hospital of Wenzhou Medical University \/ WanBangDe Pharmaceutical"},{"orgOrder":0,"company":"Oystershell NV","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Butyl Acetate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oystershell NV","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oystershell NV \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Oystershell NV \/ Undisclosed"},{"orgOrder":0,"company":"Oystershell NV","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Butyl Acetate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oystershell NV","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oystershell NV \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Oystershell NV \/ Undisclosed"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Helmholtz Centre for Infection Research | GSK | University of Oxford | University of Cologne","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"C. Difficile Spore","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Leiden University Medical Center \/ Helmholtz Centre for Infection Research | GSK | University of Oxford | University of Cologne","highestDevelopmentStatusID":"1","companyTruncated":"Leiden University Medical Center \/ Helmholtz Centre for Infection Research | GSK | University of Oxford | University of Cologne"},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"Jianmin Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Calculus Bovis Sativus","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tongji Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tongji Hospital \/ Jianmin Pharmaceutical Group","highestDevelopmentStatusID":"1","companyTruncated":"Tongji Hospital \/ Jianmin Pharmaceutical Group"},{"orgOrder":0,"company":"VaxAlta","sponsor":"Scandinavian Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Campylobacter Jejuni Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VaxAlta","amount2":0.10000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"VaxAlta \/ Scandinavian Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"VaxAlta \/ Scandinavian Biopharma"},{"orgOrder":0,"company":"CanXida","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Canxida Remove Formula Rmv","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CanXida","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanXida \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"CanXida \/ Citruslabs"},{"orgOrder":0,"company":"Anewsha Therapeutics Inc.","sponsor":"University of Michigan | Biologics Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"CBDRA60","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anewsha Therapeutics Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anewsha Therapeutics Inc. \/ University of Michigan | Biologics Consulting","highestDevelopmentStatusID":"1","companyTruncated":"Anewsha Therapeutics Inc. \/ University of Michigan | Biologics Consulting"},{"orgOrder":0,"company":"Dentaid","sponsor":"Methodex","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cetylpyridinium Chloride","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dentaid","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Dentaid \/ Methodex","highestDevelopmentStatusID":"1","companyTruncated":"Dentaid \/ Methodex"},{"orgOrder":0,"company":"University Hospitals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cetylpyridinium Chloride","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University Hospitals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospitals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"University Hospitals \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Province Centers for Disease Control and Prevention","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Chengdu Kanghua","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Jiangsu Province Centers for Disease Control and Prevention","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Province Centers for Disease Control and Prevention \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Jiangsu Province Centers for Disease Control and Prevention \/ Undisclosed"},{"orgOrder":0,"company":"Chulalongkorn University","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Chimeric JE Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chulalongkorn University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chulalongkorn University \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Chulalongkorn University \/ Sanofi"},{"orgOrder":0,"company":"Taiko Pharmaceutical","sponsor":"Kitasato University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chlorine Dioxide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Taiko Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Taiko Pharmaceutical \/ Kitasato University","highestDevelopmentStatusID":"1","companyTruncated":"Taiko Pharmaceutical \/ Kitasato University"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"CHO-DG44","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aragen Life Sciences \/ Serum Institute of India","highestDevelopmentStatusID":"1","companyTruncated":"Aragen Life Sciences \/ Serum Institute of India"},{"orgOrder":0,"company":"NIZO Food Research","sponsor":"FrieslandCampina","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Cholera Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NIZO Food Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIZO Food Research \/ FrieslandCampina","highestDevelopmentStatusID":"1","companyTruncated":"NIZO Food Research \/ FrieslandCampina"},{"orgOrder":0,"company":"NIZO Food Research","sponsor":"FrieslandCampina","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Cholera Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NIZO Food Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NIZO Food Research \/ FrieslandCampina","highestDevelopmentStatusID":"1","companyTruncated":"NIZO Food Research \/ FrieslandCampina"},{"orgOrder":0,"company":"Biotron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cinnamoylguanidine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biotron","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotron \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Biotron \/ Undisclosed"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CK0801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellenkos \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cellenkos \/ Undisclosed"},{"orgOrder":0,"company":"University of Calgary","sponsor":"Alberta Precision Laboratories | Alberta Health services | University of Alberta","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CMV-VST","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ Alberta Precision Laboratories | Alberta Health services | University of Alberta","highestDevelopmentStatusID":"1","companyTruncated":"University of Calgary \/ Alberta Precision Laboratories | Alberta Health services | University of Alberta"},{"orgOrder":0,"company":"University of Wisconsin Madison","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CoroFlu Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Wisconsin Madison","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin Madison \/ Bharat Biotech","highestDevelopmentStatusID":"1","companyTruncated":"University of Wisconsin Madison \/ Bharat Biotech"},{"orgOrder":0,"company":"Premas Biotech","sponsor":"Akers Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Coronavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Premas Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Premas Biotech \/ Akers Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Premas Biotech \/ Akers Biosciences"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Expanded Collaboration","leadProduct":"CoV RBD219-N1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CoV RBD219-N1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Baylor College of Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Baylor College of Medicine"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Soligenix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"CoVaccine HT","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BTG Specialty Pharmaceuticals \/ Soligenix","highestDevelopmentStatusID":"1","companyTruncated":"BTG Specialty Pharmaceuticals \/ Soligenix"},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"CanSino Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 mRNA-LNP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Precision NanoSystems","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision NanoSystems \/ CanSino Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Precision NanoSystems \/ CanSino Biologics"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Omicron BA.5 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"1","companyTruncated":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CYPRUS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Peptide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Axon Neuroscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axon Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Axon Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19-Adenovirus Vector-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Valo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Covimabs","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Drugs For Neglected Disease Initiative","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Oligonucleotide","year":"2020","type":"Partnership","leadProduct":"CpG-D35","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ajinomoto Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Bio-Pharma \/ Drugs For Neglected Disease Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Bio-Pharma \/ Drugs For Neglected Disease Initiative"},{"orgOrder":0,"company":"University of Arkansas, Fayetteville","sponsor":"Ocean Spray, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Cranberry Juice","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Arkansas, Fayetteville","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Arkansas, Fayetteville \/ Ocean Spray, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"University of Arkansas, Fayetteville \/ Ocean Spray, Inc."},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Culturelle Digestive Daily Probiotic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Alchem International Private Ltd","sponsor":"AIIMS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Curcuminoid","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alchem International Private Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Alchem International Private Ltd \/ AIIMS","highestDevelopmentStatusID":"1","companyTruncated":"Alchem International Private Ltd \/ AIIMS"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Cytomegalovirus-Specific Cytotoxic T Lymphocyte","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atara Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Atara Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Post Graduate Institute of Medical Education and Research, Chandigarh","sponsor":"Directorate of Health and Family Welfare, Punjab","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"DAAs","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Post Graduate Institute of Medical Education and Research, Chandigarh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Post Graduate Institute of Medical Education and Research, Chandigarh \/ Directorate of Health and Family Welfare, Punjab","highestDevelopmentStatusID":"1","companyTruncated":"Post Graduate Institute of Medical Education and Research, Chandigarh \/ Directorate of Health and Family Welfare, Punjab"},{"orgOrder":0,"company":"AmPurity Nutraceuticals, LLC","sponsor":"Arkansas Urology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Carbohydrate","year":"2018","type":"Inapplicable","leadProduct":"D-Mannose","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AmPurity Nutraceuticals, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AmPurity Nutraceuticals, LLC \/ Arkansas Urology","highestDevelopmentStatusID":"1","companyTruncated":"AmPurity Nutraceuticals, LLC \/ Arkansas Urology"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Dinona","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"DNP-019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ Dinona","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ Dinona"},{"orgOrder":0,"company":"Huro Biotech","sponsor":"Thai Binh University of Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DSM32444","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Huro Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Huro Biotech \/ Thai Binh University of Medicine and Pharmacy","highestDevelopmentStatusID":"1","companyTruncated":"Huro Biotech \/ Thai Binh University of Medicine and Pharmacy"},{"orgOrder":0,"company":"Huro Biotech","sponsor":"Vietstar Biomedical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DSM32444","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Huro Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Huro Biotech \/ Vietstar Biomedical Research","highestDevelopmentStatusID":"1","companyTruncated":"Huro Biotech \/ Vietstar Biomedical Research"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"DTaP-IPV-HepB-Hib Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Transgene","sponsor":"Vaxxel","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2020","type":"Acquisition","leadProduct":"DuckCelt-T17","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transgene \/ Vaxxel","highestDevelopmentStatusID":"1","companyTruncated":"Transgene \/ Vaxxel"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Thairm Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"EBX-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EnteroBiotix","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"EnteroBiotix \/ Thairm Bio","highestDevelopmentStatusID":"1","companyTruncated":"EnteroBiotix \/ Thairm Bio"},{"orgOrder":0,"company":"Entera Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"EnteraGam","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Entera Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entera Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Entera Health \/ Undisclosed"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Fatty acid synthase (FASN)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evasins","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"University of Oxford \/ Undisclosed"},{"orgOrder":0,"company":"Ciloa","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Exosome-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ciloa","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Ciloa \/ Bpifrance","highestDevelopmentStatusID":"1","companyTruncated":"Ciloa \/ Bpifrance"},{"orgOrder":0,"company":"PPC Pharmaceuticals","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"EZC Pak","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PPC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPC Pharmaceuticals \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"PPC Pharmaceuticals \/ Citruslabs"},{"orgOrder":0,"company":"Fluart Innovative Vaccines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HUNGARY","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"FAB-6011","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fluart Innovative Vaccines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fluart Innovative Vaccines \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Fluart Innovative Vaccines \/ Undisclosed"},{"orgOrder":0,"company":"Fluart Innovative Vaccines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HUNGARY","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"FAB-6011","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fluart Innovative Vaccines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fluart Innovative Vaccines \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Fluart Innovative Vaccines \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of Warsaw","sponsor":"Human Biome S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medical University of Warsaw","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medical University of Warsaw \/ Human Biome S.A.","highestDevelopmentStatusID":"1","companyTruncated":"Medical University of Warsaw \/ Human Biome S.A."},{"orgOrder":0,"company":"Medical University of Warsaw","sponsor":"Human Biome Institute | Medical Research Agency Poland","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medical University of Warsaw","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medical University of Warsaw \/ Human Biome Institute | Medical Research Agency Poland","highestDevelopmentStatusID":"1","companyTruncated":"Medical University of Warsaw \/ Human Biome Institute | Medical Research Agency Poland"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli | Gazi University | University of Alberta | Imperial College London | University of Debrecen | Lithuanian University of Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Fondazione Policlinico Universitario Agostino Gemelli | Gazi University | University of Alberta | Imperial College London | University of Debrecen | Lithuanian University of Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Fondazione Policlinico Universitario Agostino Gemelli | Gazi University | University of Alberta | Imperial College London | University of Debrecen | Lithuanian University of Health Sciences"},{"orgOrder":0,"company":"Vancouver Island Health Authority","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vancouver Island Health Authority","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vancouver Island Health Authority \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vancouver Island Health Authority \/ Undisclosed"},{"orgOrder":0,"company":"Vancouver Island Health Authority","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vancouver Island Health Authority","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vancouver Island Health Authority \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vancouver Island Health Authority \/ Undisclosed"},{"orgOrder":0,"company":"Hershey Medical Center","sponsor":"OpenBiome","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hershey Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Hershey Medical Center \/ OpenBiome","highestDevelopmentStatusID":"1","companyTruncated":"Hershey Medical Center \/ OpenBiome"},{"orgOrder":0,"company":"Heilongjiang Feihe Dairy Co. Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Feihe Investigational Formula","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Heilongjiang Feihe Dairy Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heilongjiang Feihe Dairy Co. Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Heilongjiang Feihe Dairy Co. Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Fertypharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Fertybiotic Balance","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fertypharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fertypharm \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Fertypharm \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Fiber","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"University Of Hawai'I At Manoa","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Filovirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ University Of Hawai\\'I At Manoa","highestDevelopmentStatusID":"1","companyTruncated":"Soligenix \/ University Of Hawai\\'I At Manoa"},{"orgOrder":0,"company":"Oakwood Laboratories","sponsor":"Flow Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"FlowVax COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oakwood Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oakwood Laboratories \/ Flow Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Oakwood Laboratories \/ Flow Pharma"},{"orgOrder":0,"company":"Fluart Innovative Vaccines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HUNGARY","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"Fluval P Monovalent Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fluart Innovative Vaccines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fluart Innovative Vaccines \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Fluart Innovative Vaccines \/ Undisclosed"},{"orgOrder":0,"company":"AB Biotics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Food Supplement","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AB Biotics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AB Biotics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotics \/ Undisclosed"},{"orgOrder":0,"company":"Endourage, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Formula C","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Endourage, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endourage, LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Endourage, LLC \/ Undisclosed"},{"orgOrder":0,"company":"PharmaJet","sponsor":"USAID","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Fractional Inactivated Poliovirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaJet \/ USAID","highestDevelopmentStatusID":"1","companyTruncated":"PharmaJet \/ USAID"},{"orgOrder":0,"company":"Universitas Padjadjaran","sponsor":"PT. Rhea Pharmaceutical Sciences Indonesia | Prodia Diacro Laboratories P.T.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Gardenia Jasminoides","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Universitas Padjadjaran","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitas Padjadjaran \/ PT. Rhea Pharmaceutical Sciences Indonesia | Prodia Diacro Laboratories P.T.","highestDevelopmentStatusID":"1","companyTruncated":"Universitas Padjadjaran \/ PT. Rhea Pharmaceutical Sciences Indonesia | Prodia Diacro Laboratories P.T."},{"orgOrder":0,"company":"DOMCA S.A.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Garlic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DOMCA S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DOMCA S.A. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"DOMCA S.A. \/ Undisclosed"},{"orgOrder":0,"company":"Genocea","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"GEN-003","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Shionogi","highestDevelopmentStatusID":"1","companyTruncated":"Genocea \/ Shionogi"},{"orgOrder":0,"company":"SmartPharm Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Gene Encoded Antibody Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SmartPharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SmartPharm Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"SmartPharm Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"GSK149203A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"The Himalaya Drug Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Guduchi","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Himalaya Drug Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Himalaya Drug Company \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"The Himalaya Drug Company \/ Undisclosed"},{"orgOrder":0,"company":"Binex","sponsor":"Genexine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"GX-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Binex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Binex \/ Genexine","highestDevelopmentStatusID":"1","companyTruncated":"Binex \/ Genexine"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"haNK","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NantKwest \/ ImmunityBio","highestDevelopmentStatusID":"1","companyTruncated":"NantKwest \/ ImmunityBio"},{"orgOrder":0,"company":"Genexine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"Hbsag Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genexine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Genexine \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"NYU Langone Health | Kenya National AIDS & STI Control Programme | National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"HCV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ NYU Langone Health | Kenya National AIDS & STI Control Programme | National Institute on Drug Abuse","highestDevelopmentStatusID":"1","companyTruncated":"Yale University \/ NYU Langone Health | Kenya National AIDS & STI Control Programme | National Institute on Drug Abuse"},{"orgOrder":0,"company":"Benha University","sponsor":"New Jeddah Clinic Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"EGYPT","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"Hepatitis B Recombinant Dna Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Benha University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Benha University \/ New Jeddah Clinic Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Benha University \/ New Jeddah Clinic Hospital"},{"orgOrder":0,"company":"Sejtterapia Kozpont","sponsor":"University of Debrecen | Ken\u00e9zy Gyula Korhaz | Szabolcs-Szatmar-Bereg County Hospital and University Teaching Hospital | Miskolc Semmelweis Hospital | Bacs-Kiskun Megyei Korhaz | UD-Genomed Kft.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HUNGARY","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Human Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sejtterapia Kozpont","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sejtterapia Kozpont \/ University of Debrecen | Ken\u00e9zy Gyula Korhaz | Szabolcs-Szatmar-Bereg County Hospital and University Teaching Hospital | Miskolc Semmelweis Hospital | Bacs-Kiskun Megyei Korhaz | UD-Genomed Kft.","highestDevelopmentStatusID":"1","companyTruncated":"Sejtterapia Kozpont \/ University of Debrecen | Ken\u00e9zy Gyula Korhaz | Szabolcs-Szatmar-Bereg County Hospital and University Teaching Hospital | Miskolc Semmelweis Hospital | Bacs-Kiskun Megyei Korhaz | UD-Genomed Kft."},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Moffitt Cancer Center \/ Merck & Co"},{"orgOrder":0,"company":"Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Human Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products \/ Bharat Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products \/ Bharat Biotech"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Ibsa Probiotic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"The Task Force for Global Health | Murdoch Childrens Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"IDA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Washington University School of Medicine \/ The Task Force for Global Health | Murdoch Childrens Research Institute","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ The Task Force for Global Health | Murdoch Childrens Research Institute"},{"orgOrder":0,"company":"XBiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IH201","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XBiotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"XBiotech \/ Undisclosed"},{"orgOrder":0,"company":"NuGenerex","sponsor":"Bintai Kinden","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Ii-Key-SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NuGenerex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NuGenerex \/ Bintai Kinden","highestDevelopmentStatusID":"1","companyTruncated":"NuGenerex \/ Bintai Kinden"},{"orgOrder":0,"company":"ImStem Biotechnology","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Licensing Agreement","leadProduct":"IMS001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImStem Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImStem Biotechnology \/ AgeX Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"ImStem Biotechnology \/ AgeX Therapeutics"},{"orgOrder":0,"company":"Pleuran, s.r.o.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Imunoglukan P4H","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pleuran, s.r.o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Pleuran, s.r.o. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pleuran, s.r.o. \/ Undisclosed"},{"orgOrder":0,"company":"Intravacc","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Inactivated EV D68 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Intravacc","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Intravacc \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Intravacc \/ National Institutes of Health"},{"orgOrder":0,"company":"Valneva","sponsor":"Batavia Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Inactivated Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ Batavia Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"Valneva \/ Batavia Bioscience"},{"orgOrder":0,"company":"Novellus","sponsor":"Novecite","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Induced Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novellus","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Novellus \/ Novecite","highestDevelopmentStatusID":"1","companyTruncated":"Novellus \/ Novecite"},{"orgOrder":0,"company":"Adimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"Influenza A H1N1 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adimmune","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adimmune \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Adimmune \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Green Cross Lab Cell","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Green Cross Lab Cell","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ Green Cross Lab Cell"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"University of Georgia Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TFF Pharmaceuticals \/ University of Georgia Research Foundation","highestDevelopmentStatusID":"1","companyTruncated":"TFF Pharmaceuticals \/ University of Georgia Research Foundation"},{"orgOrder":0,"company":"Evidation Health","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Evidation Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evidation Health \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Evidation Health \/ Sanofi"},{"orgOrder":0,"company":"Stanford Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interferon Lambda","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Stanford Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford Medicine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Stanford Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Beneo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Inulin-Type Fructan","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Beneo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beneo \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Beneo \/ Undisclosed"},{"orgOrder":0,"company":"Beneo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Inulin-Type Fructan","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Beneo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beneo \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Beneo \/ Undisclosed"},{"orgOrder":0,"company":"China Academy of Chinese Medical Sciences","sponsor":"Chengdu University of Traditional Chinese Medicine | Beijing Children's Hospital | Tianjin Infectious Disease Hospital | Tangshan Infectious Disease Hospital | The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | Tianjin Zho","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Jinlianqingre","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"China Academy of Chinese Medical Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"China Academy of Chinese Medical Sciences \/ Chengdu University of Traditional Chinese Medicine | Beijing Children's Hospital | Tianjin Infectious Disease Hospital | Tangshan Infectious Disease Hospital | The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | Tianjin Zho","highestDevelopmentStatusID":"1","companyTruncated":"China Academy of Chinese Medical Sciences \/ Chengdu University of Traditional Chinese Medicine | Beijing Children's Hospital | Tianjin Infectious Disease Hospital | Tangshan Infectious Disease Hospital | The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | Tianjin Zho"},{"orgOrder":0,"company":"FEMPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HUNGARY","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Juvia","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"FEMPHARMA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"FEMPHARMA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"FEMPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"Ab-Biotics","sponsor":"Zambon Group SpA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"KABP022","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ab-Biotics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ab-Biotics \/ Zambon Group SpA","highestDevelopmentStatusID":"1","companyTruncated":"Ab-Biotics \/ Zambon Group SpA"},{"orgOrder":0,"company":"Sao Thai Duong","sponsor":"Big Leap Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Kovir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sao Thai Duong","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sao Thai Duong \/ Big Leap Research","highestDevelopmentStatusID":"1","companyTruncated":"Sao Thai Duong \/ Big Leap Research"},{"orgOrder":0,"company":"Sao Thai Duong","sponsor":"Big Leap Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Kovir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sao Thai Duong","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sao Thai Duong \/ Big Leap Research","highestDevelopmentStatusID":"1","companyTruncated":"Sao Thai Duong \/ Big Leap Research"},{"orgOrder":0,"company":"\u00d6rebro University","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"L. reuteri DSM 17938","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"\u00d6rebro University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"\u00d6rebro University \/ BioGaia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"\u00d6rebro University \/ BioGaia Pharma"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Bandim Health Project | Arla Foods","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Lacprodan Di-8090","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Aarhus \/ Bandim Health Project | Arla Foods","highestDevelopmentStatusID":"1","companyTruncated":"University of Aarhus \/ Bandim Health Project | Arla Foods"},{"orgOrder":0,"company":"Bioithas SL","sponsor":"Centro Sperimentale del Latte S.r.l.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Lacticaseibacillus Rhamnosus CRL1505","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bioithas SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bioithas SL \/ Centro Sperimentale del Latte S.r.l.","highestDevelopmentStatusID":"1","companyTruncated":"Bioithas SL \/ Centro Sperimentale del Latte S.r.l."},{"orgOrder":0,"company":"PT Royal Medikalink Pharmalab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Lactiplantibacillus Plantarum DAD-13","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PT Royal Medikalink Pharmalab","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PT Royal Medikalink Pharmalab \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"PT Royal Medikalink Pharmalab \/ Undisclosed"},{"orgOrder":0,"company":"Inner Mongolia Yili Industrial Group Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Lactobacillus","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Inner Mongolia Yili Industrial Group Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inner Mongolia Yili Industrial Group Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Inner Mongolia Yili Industrial Group Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kerry Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kerry Group \/ Undisclosed"},{"orgOrder":0,"company":"Toronto Metropolitan University","sponsor":"Chr. Hansen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Lactobacillus GR-1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Toronto Metropolitan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toronto Metropolitan University \/ Chr. Hansen","highestDevelopmentStatusID":"1","companyTruncated":"Toronto Metropolitan University \/ Chr. Hansen"},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"TCI Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Johnsonii","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chung Shan Medical University \/ TCI Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Chung Shan Medical University \/ TCI Co., Ltd."},{"orgOrder":0,"company":"Hvidovre University Hospital","sponsor":"Chr. Hansen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Lactobacillus Probiotic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hvidovre University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hvidovre University Hospital \/ Chr. Hansen","highestDevelopmentStatusID":"1","companyTruncated":"Hvidovre University Hospital \/ Chr. Hansen"},{"orgOrder":0,"company":"Noos S.r.l.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri DSM 17938","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Noos S.r.l.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noos S.r.l. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Noos S.r.l. \/ Undisclosed"},{"orgOrder":0,"company":"Fonterra Research Centre","sponsor":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NEW ZEALAND","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Lactobacillus Rhamnosus","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fonterra Research Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fonterra Research Centre \/ Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Sprim Advanced Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Fonterra Research Centre \/ Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Sprim Advanced Life Sciences"},{"orgOrder":0,"company":"ProbiSearch SL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Salivarius","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ProbiSearch SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProbiSearch SL \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ProbiSearch SL \/ Undisclosed"},{"orgOrder":0,"company":"ProbiSearch SL","sponsor":"Casen Recordati","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Lactobacillus salivarius V4II-90","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ProbiSearch SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProbiSearch SL \/ Casen Recordati","highestDevelopmentStatusID":"1","companyTruncated":"ProbiSearch SL \/ Casen Recordati"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Strain","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kerry Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kerry Group \/ Undisclosed"},{"orgOrder":0,"company":"Montefarmaco OTC SpA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Lactoflorene Plus","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Montefarmaco OTC SpA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Montefarmaco OTC SpA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Montefarmaco OTC SpA \/ Undisclosed"},{"orgOrder":0,"company":"Vesale Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Lactogyn","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vesale Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vesale Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vesale Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Aristotle University Of Thessaloniki","sponsor":"Uni-Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GREECE","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Lactolevure","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aristotle University Of Thessaloniki","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aristotle University Of Thessaloniki \/ Uni-Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Aristotle University Of Thessaloniki \/ Uni-Pharma"},{"orgOrder":0,"company":"University of Bari","sponsor":"Uni-Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactolevure","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Bari","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Bari \/ Uni-Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Bari \/ Uni-Pharma"},{"orgOrder":0,"company":"Federal Biomedical Agency of Russia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leitragin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Federal Biomedical Agency of Russia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Federal Biomedical Agency of Russia \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Federal Biomedical Agency of Russia \/ Undisclosed"},{"orgOrder":0,"company":"EpiVax","sponsor":"Generex Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Li-Key Peptide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpiVax \/ Generex Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"EpiVax \/ Generex Biotechnology"},{"orgOrder":0,"company":"Church & Dwight Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Limosilactobacillus Reuteri 3613","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Church & Dwight Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Church & Dwight Co \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Church & Dwight Co \/ Undisclosed"},{"orgOrder":0,"company":"Synbio Tech Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"LP28","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Synbio Tech Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synbio Tech Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Synbio Tech Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Lumbar Puncture","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Pasteur \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Reig Jofre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Manremyc","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Reig Jofre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reig Jofre \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Reig Jofre \/ Undisclosed"},{"orgOrder":0,"company":"Meiji China Investment Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Meiji Yogurt Group","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Meiji China Investment Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meiji China Investment Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Meiji China Investment Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Minnesota \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"University of Minnesota \/ Undisclosed"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MG1111","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GC Biopharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"GC Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Bari","sponsor":"Heinz Italia SpA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Milk Fermented with Lactobacillus Paracasei CBA L74","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Bari","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"University of Bari \/ Heinz Italia SpA","highestDevelopmentStatusID":"1","companyTruncated":"University of Bari \/ Heinz Italia SpA"},{"orgOrder":0,"company":"NIZO Food Research","sponsor":"Arla Foods | Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Milk Protein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NIZO Food Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"NIZO Food Research \/ Arla Foods | Denmark","highestDevelopmentStatusID":"1","companyTruncated":"NIZO Food Research \/ Arla Foods | Denmark"},{"orgOrder":0,"company":"Danone Global Research & Innovation Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Mineral Water","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Danone Global Research & Innovation Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danone Global Research & Innovation Center \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Danone Global Research & Innovation Center \/ Undisclosed"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Modified Horsepox Virus Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"1","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Southern Research","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Modified Horsepox Virus Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Southern Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Southern Research \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"1","companyTruncated":"Southern Research \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TriLink BioTechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriLink BioTechnologies \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"TriLink BioTechnologies \/ Department of Defense"},{"orgOrder":0,"company":"Acuitas","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA-LNP Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acuitas \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ Pfizer Inc"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"NEXT CRO","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Multistrain Probiotic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Archer Daniels Midland \/ NEXT CRO","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ NEXT CRO"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Karolinska University Hospital | Tine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"Multi-Strain Probiotic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ Karolinska University Hospital | Tine","highestDevelopmentStatusID":"1","companyTruncated":"Oslo University Hospital \/ Karolinska University Hospital | Tine"},{"orgOrder":0,"company":"AlloVir","sponsor":"Center for Cell and Gene Therapy, Baylor College of Medicine | Baylor College of Medicine | The Methodist Hospital Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Multivirus-Specific T Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlloVir \/ Center for Cell and Gene Therapy, Baylor College of Medicine | Baylor College of Medicine | The Methodist Hospital Research Institute","highestDevelopmentStatusID":"1","companyTruncated":"AlloVir \/ Center for Cell and Gene Therapy, Baylor College of Medicine | Baylor College of Medicine | The Methodist Hospital Research Institute"},{"orgOrder":0,"company":"Corporacion Ecuatoriana de Biotecnologia","sponsor":"Universidad Central del Ecuador","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ECUADOR","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Multivitamin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Corporacion Ecuatoriana de Biotecnologia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corporacion Ecuatoriana de Biotecnologia \/ Universidad Central del Ecuador","highestDevelopmentStatusID":"1","companyTruncated":"Corporacion Ecuatoriana de Biotecnologia \/ Universidad Central del Ecuador"},{"orgOrder":0,"company":"Regina Esiovwa","sponsor":"University of the West of Scotland | Brunel Healthcare Manufacturing Limited | Partec Nigeria | Panets Education Trust for Africa (PETA) | Lagos State University | Nigerian Institute of Medical Research | Scottish Trace Element and Micronutrient Diagnosti","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Multivitamin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Regina Esiovwa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regina Esiovwa \/ University of the West of Scotland | Brunel Healthcare Manufacturing Limited | Partec Nigeria | Panets Education Trust for Africa (PETA) | Lagos State University | Nigerian Institute of Medical Research | Scottish Trace Element and Micronutrient Diagnosti","highestDevelopmentStatusID":"1","companyTruncated":"Regina Esiovwa \/ University of the West of Scotland | Brunel Healthcare Manufacturing Limited | Partec Nigeria | Panets Education Trust for Africa (PETA) | Lagos State University | Nigerian Institute of Medical Research | Scottish Trace Element and Micronutrient Diagnosti"},{"orgOrder":0,"company":"Tilman","sponsor":"Artialis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Nasafytol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tilman","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tilman \/ Artialis","highestDevelopmentStatusID":"1","companyTruncated":"Tilman \/ Artialis"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"nCoV-2019 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"Glory Kingdom Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Nettle","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chung Shan Medical University \/ Glory Kingdom Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Chung Shan Medical University \/ Glory Kingdom Corporation"},{"orgOrder":0,"company":"EpiVax","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Nucleic acid Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"EpiVax \/ Immunomic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"EpiVax \/ Immunomic Therapeutics"},{"orgOrder":0,"company":"Manresana de Micobacteriologia, SL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Nyaditum Resae","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Manresana de Micobacteriologia, SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Manresana de Micobacteriologia, SL \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Manresana de Micobacteriologia, SL \/ Undisclosed"},{"orgOrder":0,"company":"Manresana de Micobacteriologia, SL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Nyaditum Resae 10E4","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Manresana de Micobacteriologia, SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Manresana de Micobacteriologia, SL \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Manresana de Micobacteriologia, SL \/ Undisclosed"},{"orgOrder":0,"company":"Open Orphan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"OC43 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Open Orphan","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Open Orphan \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Open Orphan \/ Undisclosed"},{"orgOrder":0,"company":"Rutgers, The State University of New Jersey","sponsor":"Vault Health, Inc. | Danisco USA Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"OL-1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rutgers, The State University of New Jersey","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rutgers, The State University of New Jersey \/ Vault Health, Inc. | Danisco USA Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Rutgers, The State University of New Jersey \/ Vault Health, Inc. | Danisco USA Inc."},{"orgOrder":0,"company":"Kerecis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ICELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Omega3 Viruxide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kerecis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Kerecis \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kerecis \/ Undisclosed"},{"orgOrder":0,"company":"Anhui Zhifei Longcom Biologic Pharmacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Omicron BA.4\/5-Delta Recombinant Protein COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anhui Zhifei Longcom Biologic Pharmacy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed"},{"orgOrder":0,"company":"Anhui Zhifei Longcom Biologic Pharmacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Omicron BA.4\/5-Delta Recombinant Protein COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anhui Zhifei Longcom Biologic Pharmacy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Udine, Italy","sponsor":"Winclove Probiotics B.V. | Institut Allergosan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"OMNi-BiOTiC 41167","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University Hospital, Udine, Italy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Udine, Italy \/ Winclove Probiotics B.V. | Institut Allergosan","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital, Udine, Italy \/ Winclove Probiotics B.V. | Institut Allergosan"},{"orgOrder":0,"company":"Omnilife Manufactura, SA de CV","sponsor":"University of Guadalajara","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MEXICO","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Omniplus Supreme","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Omnilife Manufactura, SA de CV","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omnilife Manufactura, SA de CV \/ University of Guadalajara","highestDevelopmentStatusID":"1","companyTruncated":"Omnilife Manufactura, SA de CV \/ University of Guadalajara"},{"orgOrder":0,"company":"EpiVax","sponsor":"Intravacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"OMV-peptide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpiVax \/ Intravacc","highestDevelopmentStatusID":"1","companyTruncated":"EpiVax \/ Intravacc"},{"orgOrder":0,"company":"Aga Khan University","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"PAKISTAN","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"Oral Poliovirus Type 1 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aga Khan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aga Khan University \/ World Health Organization","highestDevelopmentStatusID":"1","companyTruncated":"Aga Khan University \/ World Health Organization"},{"orgOrder":0,"company":"Alexandra Papadopoulou","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Ors Rehydration Solution","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alexandra Papadopoulou","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alexandra Papadopoulou \/ BioGaia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Alexandra Papadopoulou \/ BioGaia Pharma"},{"orgOrder":0,"company":"University of the Witwatersrand","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ox1Cov-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of the Witwatersrand","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of the Witwatersrand \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"University of the Witwatersrand \/ Undisclosed"},{"orgOrder":0,"company":"National Research Council of Canada","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Pan-Coronavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Research Council of Canada","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Research Council of Canada \/ VBI Vaccines","highestDevelopmentStatusID":"1","companyTruncated":"National Research Council of Canada \/ VBI Vaccines"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"United States Agency for International Development | World Health Organization | Cairo University | University Hospital for Infectious Diseases, Croatia | Universidade Federal do Rio de Janeiro","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Benzathine Penicillin G","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ United States Agency for International Development | World Health Organization | Cairo University | University Hospital for Infectious Diseases, Croatia | Universidade Federal do Rio de Janeiro","highestDevelopmentStatusID":"1","companyTruncated":"Johns Hopkins University \/ United States Agency for International Development | World Health Organization | Cairo University | University Hospital for Infectious Diseases, Croatia | Universidade Federal do Rio de Janeiro"},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Valo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Peptide Based-pan Coronavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImmunoScape","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoScape \/ Valo Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"ImmunoScape \/ Valo Therapeutics"},{"orgOrder":0,"company":"Turn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Petrolatum","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Turn Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Turn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VIDO-InterVac","sponsor":"ZYUS Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Plant Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VIDO-InterVac","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VIDO-InterVac \/ ZYUS Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"VIDO-InterVac \/ ZYUS Life Sciences"},{"orgOrder":0,"company":"iBio","sponsor":"CC-Pharming","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Plant Derived Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"iBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iBio \/ CC-Pharming","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ CC-Pharming"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Takara Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Plasmid Dna Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Takara Bio","highestDevelopmentStatusID":"1","companyTruncated":"AGC Biologics \/ Takara Bio"},{"orgOrder":0,"company":"Pluri","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"PLX Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pluri \/ Undisclosed"},{"orgOrder":0,"company":"Centers for Disease Control and Prevention, China","sponsor":"Beijing Municipal Health Bureau | Beijing Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Pneumococcal 7-valent Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Centers for Disease Control and Prevention, China","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centers for Disease Control and Prevention, China \/ Beijing Municipal Health Bureau | Beijing Center for Disease Control and Prevention","highestDevelopmentStatusID":"1","companyTruncated":"Centers for Disease Control and Prevention, China \/ Beijing Municipal Health Bureau | Beijing Center for Disease Control and Prevention"},{"orgOrder":0,"company":"Vabiotech","sponsor":"Vietstar Biomedical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vabiotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vabiotech \/ Vietstar Biomedical Research","highestDevelopmentStatusID":"1","companyTruncated":"Vabiotech \/ Vietstar Biomedical Research"},{"orgOrder":0,"company":"Emery Pharma","sponsor":"Halodine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emery Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Emery Pharma \/ Halodine","highestDevelopmentStatusID":"1","companyTruncated":"Emery Pharma \/ Halodine"},{"orgOrder":0,"company":"Happy V","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Prebiotic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Happy V","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Happy V \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Happy V \/ Citruslabs"},{"orgOrder":0,"company":"Sprim Advanced Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Prebiotics","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sprim Advanced Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sprim Advanced Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sprim Advanced Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"Friends in Global Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"PrEP","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt University Medical Center \/ Friends in Global Health","highestDevelopmentStatusID":"1","companyTruncated":"Vanderbilt University Medical Center \/ Friends in Global Health"},{"orgOrder":0,"company":"Probi AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Probi Defendum","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Probi AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Probi AB \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Probi AB \/ Undisclosed"},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiokid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Promitor","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"University of Melbourne","sponsor":"Medical Research Future Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Protein Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Melbourne","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Melbourne \/ Medical Research Future Fund","highestDevelopmentStatusID":"1","companyTruncated":"University of Melbourne \/ Medical Research Future Fund"},{"orgOrder":0,"company":"Skane University Hospital","sponsor":"University of California, Davis | Ume\u00e5 University | Arla Foods","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Protein-Reduced Whey","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Skane University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skane University Hospital \/ University of California, Davis | Ume\u00e5 University | Arla Foods","highestDevelopmentStatusID":"1","companyTruncated":"Skane University Hospital \/ University of California, Davis | Ume\u00e5 University | Arla Foods"},{"orgOrder":0,"company":"Mackay Memorial Hospital","sponsor":"Bened Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"PS23","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mackay Memorial Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mackay Memorial Hospital \/ Bened Biomedical","highestDevelopmentStatusID":"1","companyTruncated":"Mackay Memorial Hospital \/ Bened Biomedical"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Sensory Cloud","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"PUR 003","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Pulmatrix \/ Sensory Cloud","highestDevelopmentStatusID":"1","companyTruncated":"Pulmatrix \/ Sensory Cloud"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"Quadrivalent Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"The University of Pittsburgh School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Institut Pasteur du Cambodge | Institut Pasteur de Madagascar","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Pasteur \/ Institut Pasteur du Cambodge | Institut Pasteur de Madagascar","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ Institut Pasteur du Cambodge | Institut Pasteur de Madagascar"},{"orgOrder":0,"company":"Eastern Virginia Medical School","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Human Papillomavirus Quadrivalent Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Eastern Virginia Medical School","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eastern Virginia Medical School \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Eastern Virginia Medical School \/ Merck & Co"},{"orgOrder":0,"company":"SPP Pharmaclon Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Interferon gamma-1b","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SPP Pharmaclon Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SPP Pharmaclon Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"SPP Pharmaclon Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"AntiCancer","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Methioninase","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AntiCancer","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AntiCancer \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AntiCancer \/ Undisclosed"},{"orgOrder":0,"company":"Manhattan BioSolutions","sponsor":"Nascent Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Recombinant Mycobacterium Bovis Bacillus Calmette-Guerin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Manhattan BioSolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Manhattan BioSolutions \/ Nascent Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Manhattan BioSolutions \/ Nascent Biotech"},{"orgOrder":0,"company":"Anhui Zhifei Longcom Biologic Pharmacy","sponsor":"The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Omicron-Delta COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anhui Zhifei Longcom Biologic Pharmacy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anhui Zhifei Longcom Biologic Pharmacy \/ The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"1","companyTruncated":"Anhui Zhifei Longcom Biologic Pharmacy \/ The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"Jiangsu Kanion Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Reduning","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Jiangsu Kanion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Kanion Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Jiangsu Kanion Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ogevity Therapeutics, Inc.","sponsor":"National University of Singapore","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Reduxium","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ogevity Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ogevity Therapeutics, Inc. \/ National University of Singapore","highestDevelopmentStatusID":"1","companyTruncated":"Ogevity Therapeutics, Inc. \/ National University of Singapore"},{"orgOrder":0,"company":"University of Miami","sponsor":"Daiwa Health Development","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Rice Bran Arabinoxylan","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ Daiwa Health Development","highestDevelopmentStatusID":"1","companyTruncated":"University of Miami \/ Daiwa Health Development"},{"orgOrder":0,"company":"Rothschild Foundation Hospital","sponsor":"Hotel Dieu Hospital | Institut Pasteur | Hopital Lariboisi\u00e8re","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"RT-PCR SARS-CoV-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rothschild Foundation Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Swab","sponsorNew":"Rothschild Foundation Hospital \/ Hotel Dieu Hospital | Institut Pasteur | Hopital Lariboisi\u00e8re","highestDevelopmentStatusID":"1","companyTruncated":"Rothschild Foundation Hospital \/ Hotel Dieu Hospital | Institut Pasteur | Hopital Lariboisi\u00e8re"},{"orgOrder":0,"company":"Archivel Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RUTI Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Archivel Farma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Archivel Farma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Archivel Farma \/ Undisclosed"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Dyadic International, Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"rVaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Israel Institute for Biological Research \/ Dyadic International, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Israel Institute for Biological Research \/ Dyadic International, Inc"},{"orgOrder":0,"company":"John Hale","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"S. salivarius K12","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"John Hale","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"John Hale \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"John Hale \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SA58","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Beijing Ditan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SA58","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sinovac Biotech \/ Beijing Ditan Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Sinovac Biotech \/ Beijing Ditan Hospital"},{"orgOrder":0,"company":"Covar Pharmaceuticals","sponsor":"Aptorum","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"SACT-COV19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Covar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Covar Pharmaceuticals \/ Aptorum","highestDevelopmentStatusID":"1","companyTruncated":"Covar Pharmaceuticals \/ Aptorum"},{"orgOrder":0,"company":"VaxEquity","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"saRNA Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VaxEquity","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VaxEquity \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"VaxEquity \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Griffith University","sponsor":"Indian Immunologicals Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"SARS \u2013 CoV-2 Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Griffith University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Griffith University \/ Indian Immunologicals Limited","highestDevelopmentStatusID":"1","companyTruncated":"Griffith University \/ Indian Immunologicals Limited"},{"orgOrder":0,"company":"Sanofi","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"SARS Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ BARDA"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"AdaptVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"SARS-CoV-2 Capsid-Virus-like Particle Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ AdaptVac","highestDevelopmentStatusID":"1","companyTruncated":"AGC Biologics \/ AdaptVac"},{"orgOrder":0,"company":"AdventHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SARSCoV2 Convalescent Plasma","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AdventHealth","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AdventHealth \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AdventHealth \/ Undisclosed"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 mRNA Vaccine Bivalent","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"1","companyTruncated":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Omicron BA.5 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"1","companyTruncated":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Omicron BA.5 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"1","companyTruncated":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"The First Affiliated Hospital of Bengbu Medical University | Ningbo Rongan Biological Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"SARS-CoV-2 Omicron BA.5 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AIM Vaccine \/ The First Affiliated Hospital of Bengbu Medical University | Ningbo Rongan Biological Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"AIM Vaccine \/ The First Affiliated Hospital of Bengbu Medical University | Ningbo Rongan Biological Pharmaceutical"},{"orgOrder":0,"company":"Vaccine and Immunotherapy Center","sponsor":"Voltron Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Self-Assembling Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vaccine and Immunotherapy Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaccine and Immunotherapy Center \/ Voltron Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Vaccine and Immunotherapy Center \/ Voltron Therapeutics"},{"orgOrder":0,"company":"George Mason University","sponsor":"Gylden Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Set-Point Vaccines","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"George Mason University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"George Mason University \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"1","companyTruncated":"George Mason University \/ Emergex Vaccines Holding"},{"orgOrder":0,"company":"SIWA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SIWA 318H","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SIWA Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIWA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"SIWA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"University Of Natural Resources","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"S-Layer COVID Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avalon GloboCare","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avalon GloboCare \/ University Of Natural Resources","highestDevelopmentStatusID":"1","companyTruncated":"Avalon GloboCare \/ University Of Natural Resources"},{"orgOrder":0,"company":"Medi Pharma Vision","sponsor":"Veterinary Research Institute | Brno University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Smartprobio C","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medi Pharma Vision","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medi Pharma Vision \/ Veterinary Research Institute | Brno University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Medi Pharma Vision \/ Veterinary Research Institute | Brno University Hospital"},{"orgOrder":0,"company":"Taipei Medical University WanFang Hospital","sponsor":"Febico (Far East Bio-Tec Co Ltd)","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Spirulina","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Taipei Medical University WanFang Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taipei Medical University WanFang Hospital \/ Febico (Far East Bio-Tec Co Ltd)","highestDevelopmentStatusID":"1","companyTruncated":"Taipei Medical University WanFang Hospital \/ Febico (Far East Bio-Tec Co Ltd)"},{"orgOrder":0,"company":"OSF Healthcare System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Stool","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"OSF Healthcare System","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"OSF Healthcare System \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"OSF Healthcare System \/ Undisclosed"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"S-Trimer","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Carbohydrate","year":"2020","type":"Termination","leadProduct":"Sucrose Acetate Isobutyrate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Durect Corporation","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Durect Corporation \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Durect Corporation \/ Gilead Sciences"},{"orgOrder":0,"company":"University of Hong Kong","sponsor":"Sysmex Asia Pacific","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Sysmex UF-5000 system","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Hong Kong","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Hong Kong \/ Sysmex Asia Pacific","highestDevelopmentStatusID":"1","companyTruncated":"University of Hong Kong \/ Sysmex Asia Pacific"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"T89","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"T89","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Tianjin Tasly Group","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin Tasly Group \/ Tianjin Tasly Group"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TAK-888","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TAK-888","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Centre Hospitalier R\u00e9gional Metz-Thionville","sponsor":"centre r\u00e9gional de pharmacovigilance de Nancy | Theradial","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Taurolock","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Centre Hospitalier R\u00e9gional Metz-Thionville","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Centre Hospitalier R\u00e9gional Metz-Thionville \/ centre r\u00e9gional de pharmacovigilance de Nancy | Theradial","highestDevelopmentStatusID":"1","companyTruncated":"Centre Hospitalier R\u00e9gional Metz-Thionville \/ centre r\u00e9gional de pharmacovigilance de Nancy | Theradial"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"TCI188","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Noachis Terra","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"Terra CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Noachis Terra","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noachis Terra \/ Oragenics","highestDevelopmentStatusID":"1","companyTruncated":"Noachis Terra \/ Oragenics"},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Terra CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avid Bioservices","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avid Bioservices \/ Oragenics","highestDevelopmentStatusID":"1","companyTruncated":"Avid Bioservices \/ Oragenics"},{"orgOrder":0,"company":"Premas Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Triple Antigen Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Premas Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Premas Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Premas Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Center for Cell and Gene Therapy, Baylor College of Medicine | The Methodist Hospital Research Institute | Children's Hospital Los Angeles | Duke University | Hackensack Meridian Health | New York Medical College | UT Southwestern Medical Center | Childre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Trivirus-Specific CTLs","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylor College of Medicine \/ Center for Cell and Gene Therapy, Baylor College of Medicine | The Methodist Hospital Research Institute | Children's Hospital Los Angeles | Duke University | Hackensack Meridian Health | New York Medical College | UT Southwestern Medical Center | Childre","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Center for Cell and Gene Therapy, Baylor College of Medicine | The Methodist Hospital Research Institute | Children's Hospital Los Angeles | Duke University | Hackensack Meridian Health | New York Medical College | UT Southwestern Medical Center | Childre"},{"orgOrder":0,"company":"National Cheng-Kung University Hospital","sponsor":"Grape King Bio Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Troches","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Cheng-Kung University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"National Cheng-Kung University Hospital \/ Grape King Bio Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"National Cheng-Kung University Hospital \/ Grape King Bio Ltd."},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Wuhan Hamilton Bio-technology Co., Ltd, China.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuhan Union Hospital \/ Wuhan Hamilton Bio-technology Co., Ltd, China.","highestDevelopmentStatusID":"1","companyTruncated":"Wuhan Union Hospital \/ Wuhan Hamilton Bio-technology Co., Ltd, China."},{"orgOrder":0,"company":"Impatients N.V. trading as myTomorrows","sponsor":"Inmunotek","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Uromune","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Impatients N.V. trading as myTomorrows","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Impatients N.V. trading as myTomorrows \/ Inmunotek","highestDevelopmentStatusID":"1","companyTruncated":"Impatients N.V. trading as myTomorrows \/ Inmunotek"},{"orgOrder":0,"company":"Vabiotech","sponsor":"Vietstar Biomedical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vabiotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vabiotech \/ Vietstar Biomedical Research","highestDevelopmentStatusID":"1","companyTruncated":"Vabiotech \/ Vietstar Biomedical Research"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Saint Etienne","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Centre Hospitalier Universitaire de Saint Etienne","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Universitaire de Saint Etienne \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Centre Hospitalier Universitaire de Saint Etienne \/ Sanofi"},{"orgOrder":0,"company":"Fytexia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Verum","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fytexia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fytexia \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Fytexia \/ Undisclosed"},{"orgOrder":0,"company":"The Herb, Inc","sponsor":"Prorelix Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Viracide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Herb, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Herb, Inc \/ Prorelix Research","highestDevelopmentStatusID":"1","companyTruncated":"The Herb, Inc \/ Prorelix Research"},{"orgOrder":0,"company":"Akron Biotech","sponsor":"Octapharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Partnership","leadProduct":"Virally Inactivated Human AB Serum","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Akron Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akron Biotech \/ Octapharma","highestDevelopmentStatusID":"1","companyTruncated":"Akron Biotech \/ Octapharma"},{"orgOrder":0,"company":"ImmuneMed, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Virus Suppressing Factor","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImmuneMed, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuneMed, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ImmuneMed, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Catalysis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Viusid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalysis \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Catalysis \/ Undisclosed"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Spicona","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"VLP Based COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Spicona","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ Spicona"},{"orgOrder":0,"company":"3PBiovian","sponsor":"SpyBiotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"VLP Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"3PBiovian","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3PBiovian \/ SpyBiotech","highestDevelopmentStatusID":"1","companyTruncated":"3PBiovian \/ SpyBiotech"},{"orgOrder":0,"company":"Max Planck Institute for Infection Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VPM1002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Max Planck Institute for Infection Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Max Planck Institute for Infection Biology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Max Planck Institute for Infection Biology \/ Undisclosed"},{"orgOrder":0,"company":"Kemin Foods LC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Whole Cell Algae Fermentate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kemin Foods LC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kemin Foods LC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kemin Foods LC \/ Undisclosed"},{"orgOrder":0,"company":"The Chumakov Federal Scientific Center","sponsor":"Vektor State Research Center Of Virology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Whole-Virion Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Chumakov Federal Scientific Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Chumakov Federal Scientific Center \/ Vektor State Research Center Of Virology","highestDevelopmentStatusID":"1","companyTruncated":"The Chumakov Federal Scientific Center \/ Vektor State Research Center Of Virology"},{"orgOrder":0,"company":"Oystershell NV","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"X92001752","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oystershell NV","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Oystershell NV \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Oystershell NV \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"XC8","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine | Affiliated Hospital of Liaoning University of Traditional Chinese Medicine | Beijing Luhe Hospital | Qingdao Municipal Hospital | Cangzhou People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Xiyanping","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingfeng Pharmaceutical Group \/ The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine | Affiliated Hospital of Liaoning University of Traditional Chinese Medicine | Beijing Luhe Hospital | Qingdao Municipal Hospital | Cangzhou People's Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Qingfeng Pharmaceutical Group \/ The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine | Affiliated Hospital of Liaoning University of Traditional Chinese Medicine | Beijing Luhe Hospital | Qingdao Municipal Hospital | Cangzhou People's Hospital"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"China Academy of Chinese Medical Sciences | Beijing YouAn Hospital | The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | Beijing University of Chinese Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Xiyanping","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingfeng Pharmaceutical Group \/ China Academy of Chinese Medical Sciences | Beijing YouAn Hospital | The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | Beijing University of Chinese Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Qingfeng Pharmaceutical Group \/ China Academy of Chinese Medical Sciences | Beijing YouAn Hospital | The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | Beijing University of Chinese Medicine"},{"orgOrder":0,"company":"Ministry of Public Health, Argentina","sponsor":"Centers for Disease Control and Prevention | Pan American Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ARGENTINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Yellow Fever Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ministry of Public Health, Argentina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ministry of Public Health, Argentina \/ Centers for Disease Control and Prevention | Pan American Health Organization","highestDevelopmentStatusID":"1","companyTruncated":"Ministry of Public Health, Argentina \/ Centers for Disease Control and Prevention | Pan American Health Organization"},{"orgOrder":0,"company":"Excivion","sponsor":"Coordination Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Zika-HX Antigen","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Excivion","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Excivion \/ CPI","highestDevelopmentStatusID":"1","companyTruncated":"Excivion \/ CPI"},{"orgOrder":0,"company":"Aga Khan University","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"PAKISTAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Zinc Sulphate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aga Khan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Aga Khan University \/ World Health Organization","highestDevelopmentStatusID":"1","companyTruncated":"Aga Khan University \/ World Health Organization"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"Radiolabelled MNPR-101","moa":"uPAR","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"1","companyTruncated":"Monopar Therapeutics \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Cascade Chemistry","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cascade Chemistry","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cascade Chemistry \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Cascade Chemistry \/ Algernon Pharmaceuticals"},{"orgOrder":0,"company":"Chengdu Zenitar Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Flunotinib Maleate","moa":"VEGFR \/ PDGFR \/ FGFR","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chengdu Zenitar Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Zenitar Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chengdu Zenitar Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nascent Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nascent Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nascent Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Espero BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Tecarfarin","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Espero BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Espero BioPharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Espero BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Obafemi Awolowo University","sponsor":"Borno State Ministry of Health | Ogun State Ministry of Health | Abia State Ministry of Health | Sokoto State Ministry of Health | Benue State Minsitry of Health | University of Calabar Teaching Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NIGERIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Obafemi Awolowo University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Obafemi Awolowo University \/ Borno State Ministry of Health | Ogun State Ministry of Health | Abia State Ministry of Health | Sokoto State Ministry of Health | Benue State Minsitry of Health | University of Calabar Teaching Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Obafemi Awolowo University \/ Borno State Ministry of Health | Ogun State Ministry of Health | Abia State Ministry of Health | Sokoto State Ministry of Health | Benue State Minsitry of Health | University of Calabar Teaching Hospital"},{"orgOrder":0,"company":"Post Graduate Institute of Medical Education and Research, Chandigarh","sponsor":"Directorate of Health and Family Welfare, Punjab","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Post Graduate Institute of Medical Education and Research, Chandigarh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Post Graduate Institute of Medical Education and Research, Chandigarh \/ Directorate of Health and Family Welfare, Punjab","highestDevelopmentStatusID":"1","companyTruncated":"Post Graduate Institute of Medical Education and Research, Chandigarh \/ Directorate of Health and Family Welfare, Punjab"},{"orgOrder":0,"company":"International Centre for Diarrhoeal Disease Research, Bangladesh","sponsor":"Community Based Medical College, Bangladesh | Dhaka Medical College | Directorate General of Health Services of Bangladesh","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BANGLADESH","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"International Centre for Diarrhoeal Disease Research, Bangladesh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Community Based Medical College, Bangladesh | Dhaka Medical College | Directorate General of Health Services of Bangladesh","highestDevelopmentStatusID":"1","companyTruncated":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Community Based Medical College, Bangladesh | Dhaka Medical College | Directorate General of Health Services of Bangladesh"},{"orgOrder":0,"company":"East China Normal University","sponsor":"ImmuneCyte Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"East China Normal University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"East China Normal University \/ ImmuneCyte Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"East China Normal University \/ ImmuneCyte Life Sciences"},{"orgOrder":0,"company":"Institute of Microbiology of the Chinese Academy of Sciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute of Microbiology of the Chinese Academy of Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Microbiology of the Chinese Academy of Sciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Institute of Microbiology of the Chinese Academy of Sciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Tianjin University","sponsor":"Beroni Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tianjin University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin University \/ Beroni Group","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin University \/ Beroni Group"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Institut Pasteur Shanghai","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alphamab Oncology \/ Institut Pasteur Shanghai","highestDevelopmentStatusID":"1","companyTruncated":"Alphamab Oncology \/ Institut Pasteur Shanghai"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanyou Biopharmaceuticals \/ Shanghai Henlius Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Sanyou Biopharmaceuticals \/ Shanghai Henlius Biotech"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Sino Biological","sponsor":"GeoVax Labs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sino Biological","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sino Biological \/ GeoVax Labs","highestDevelopmentStatusID":"1","companyTruncated":"Sino Biological \/ GeoVax Labs"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ Undisclosed"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ Vir Biotechnology"},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Aligos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Luxna Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luxna Biotech \/ Aligos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Luxna Biotech \/ Aligos Therapeutics"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Kleo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Cross Lab Cell \/ Kleo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Green Cross Lab Cell \/ Kleo Pharmaceuticals"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"OliX Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Codagenix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Serum Institute of India \/ Codagenix","highestDevelopmentStatusID":"1","companyTruncated":"Serum Institute of India \/ Codagenix"},{"orgOrder":0,"company":"Vopec Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vopec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vopec Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vopec Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"DNDi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ DNDi","highestDevelopmentStatusID":"1","companyTruncated":"Dr. Reddy\\'s Laboratories \/ DNDi"},{"orgOrder":0,"company":"Medical University of Vienna","sponsor":"Viravaxx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Azithromycin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medical University of Vienna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of Vienna \/ Viravaxx","highestDevelopmentStatusID":"1","companyTruncated":"Medical University of Vienna \/ Viravaxx"},{"orgOrder":0,"company":"Versailles Hospital","sponsor":"Institut Pasteur | Sanofi | Saint Antoine University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Versailles Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Versailles Hospital \/ Institut Pasteur | Sanofi | Saint Antoine University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Versailles Hospital \/ Institut Pasteur | Sanofi | Saint Antoine University Hospital"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Institut National de Recherche Biom\u00e9dicale | Centre National de la Recherche Scientifique, France | Universit\u00e9 Paris Cit\u00e9","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Pasteur \/ Institut National de Recherche Biom\u00e9dicale | Centre National de la Recherche Scientifique, France | Universit\u00e9 Paris Cit\u00e9","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ Institut National de Recherche Biom\u00e9dicale | Centre National de la Recherche Scientifique, France | Universit\u00e9 Paris Cit\u00e9"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"INSERM | Commissariat A L'energie Atomique | Institut Pasteur","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ INSERM | Commissariat A L'energie Atomique | Institut Pasteur","highestDevelopmentStatusID":"1","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ INSERM | Commissariat A L'energie Atomique | Institut Pasteur"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Biogroup Laboratoire de biologie m\u00e9dicale","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Pasteur \/ Biogroup Laboratoire de biologie m\u00e9dicale","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ Biogroup Laboratoire de biologie m\u00e9dicale"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"H\u00f4pital Necker-Enfants Malades | Hospices Civils de Lyon | H\u00f4pital Universitaire Robert-Debr\u00e9 | Centre Hospitalier Intercommunal Creteil | Nantes University Hospital | R\u00e9seau ACTIV | H\u00f4pital Armand Trousseau | CHR - H\u00f4pital Roger Salengo | H\u00f4pital Nord - ","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Pasteur \/ H\u00f4pital Necker-Enfants Malades | Hospices Civils de Lyon | H\u00f4pital Universitaire Robert-Debr\u00e9 | Centre Hospitalier Intercommunal Creteil | Nantes University Hospital | R\u00e9seau ACTIV | H\u00f4pital Armand Trousseau | CHR - H\u00f4pital Roger Salengo | H\u00f4pital Nord - ","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ H\u00f4pital Necker-Enfants Malades | Hospices Civils de Lyon | H\u00f4pital Universitaire Robert-Debr\u00e9 | Centre Hospitalier Intercommunal Creteil | Nantes University Hospital | R\u00e9seau ACTIV | H\u00f4pital Armand Trousseau | CHR - H\u00f4pital Roger Salengo | H\u00f4pital Nord - "},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Pasteur \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ Undisclosed"},{"orgOrder":0,"company":"Heinz Italia SpA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Heinz Italia SpA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heinz Italia SpA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Heinz Italia SpA \/ Undisclosed"},{"orgOrder":0,"company":"Hofseth Biocare ASA","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hofseth Biocare ASA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hofseth Biocare ASA \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"Hofseth Biocare ASA \/ KGK Science"},{"orgOrder":0,"company":"Hospital de Sagunto","sponsor":"Biopolis S.L. | Laboratorios Heel Espa\u00f1a","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hospital de Sagunto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital de Sagunto \/ Biopolis S.L. | Laboratorios Heel Espa\u00f1a","highestDevelopmentStatusID":"1","companyTruncated":"Hospital de Sagunto \/ Biopolis S.L. | Laboratorios Heel Espa\u00f1a"},{"orgOrder":0,"company":"Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n","sponsor":"SOLUTEX GC SL","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n \/ SOLUTEX GC SL","highestDevelopmentStatusID":"1","companyTruncated":"Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n \/ SOLUTEX GC SL"},{"orgOrder":0,"company":"Diamond Light Source","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Diamond Light Source","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diamond Light Source \/ Exscientia","highestDevelopmentStatusID":"1","companyTruncated":"Diamond Light Source \/ Exscientia"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Birmingham \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"University of Birmingham \/ Undisclosed"},{"orgOrder":0,"company":"Antabio","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Antabio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Antabio \/ CARB-X","highestDevelopmentStatusID":"1","companyTruncated":"Antabio \/ CARB-X"},{"orgOrder":0,"company":"Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UKRAINE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biopharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Oystershell NV","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oystershell NV","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Oystershell NV \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Oystershell NV \/ Undisclosed"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"ViiV Healthcare \/ GSK"},{"orgOrder":0,"company":"Oystershell NV","sponsor":"Eurofins CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oystershell NV","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oystershell NV \/ Eurofins CDMO","highestDevelopmentStatusID":"1","companyTruncated":"Oystershell NV \/ Eurofins CDMO"},{"orgOrder":0,"company":"Evonik","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Evonik","amount2":0.22,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.22,"dosageForm":"Undisclosed","sponsorNew":"Evonik \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Evonik \/ BARDA"},{"orgOrder":0,"company":"VIB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VIB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VIB \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"VIB \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Imperial College London \/ Undisclosed"},{"orgOrder":0,"company":"RQ Bio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"RQ Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RQ Bio \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"RQ Bio \/ AstraZeneca"},{"orgOrder":0,"company":"OntoChem","sponsor":"Anixa Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"OntoChem","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OntoChem \/ Anixa Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"OntoChem \/ Anixa Biosciences"},{"orgOrder":0,"company":"Bactolife","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bactolife","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Bactolife \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Bactolife \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"iosBio","sponsor":"Department of Health and Social Care","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"iosBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iosBio \/ Department of Health and Social Care","highestDevelopmentStatusID":"1","companyTruncated":"iosBio \/ Department of Health and Social Care"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bioiberica \/ Undisclosed"},{"orgOrder":0,"company":"SuperTrans Medical","sponsor":"Mediforum Pharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SuperTrans Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SuperTrans Medical \/ Mediforum Pharm","highestDevelopmentStatusID":"1","companyTruncated":"SuperTrans Medical \/ Mediforum Pharm"},{"orgOrder":0,"company":"University of Arizona","sponsor":"Sunshine Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Arizona","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Arizona \/ Sunshine Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Arizona \/ Sunshine Biopharma"},{"orgOrder":0,"company":"Mead Johnson Nutrition","sponsor":"Georgia Institute for Clinical Research, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mead Johnson Nutrition","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Mead Johnson Nutrition \/ Georgia Institute for Clinical Research, LLC","highestDevelopmentStatusID":"1","companyTruncated":"Mead Johnson Nutrition \/ Georgia Institute for Clinical Research, LLC"},{"orgOrder":0,"company":"Mead Johnson Nutrition","sponsor":"Shanghai Children's Medical Center | Shanghai, China","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mead Johnson Nutrition","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Mead Johnson Nutrition \/ Shanghai Children's Medical Center | Shanghai, China","highestDevelopmentStatusID":"1","companyTruncated":"Mead Johnson Nutrition \/ Shanghai Children's Medical Center | Shanghai, China"},{"orgOrder":0,"company":"University of Illinois","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Illinois","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Illinois \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Illinois \/ Vanda Pharmaceuticals"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Vaibhav Mokashi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Vaibhav Mokashi","highestDevelopmentStatusID":"1","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Vaibhav Mokashi"},{"orgOrder":0,"company":"Mount Sinai Hospital, Canada","sponsor":"Sault Area Hospital | Michael Garron Hospital | Unity Health Toronto | The Ottawa Hospital | Northwestern Memorial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mount Sinai Hospital, Canada","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mount Sinai Hospital, Canada \/ Sault Area Hospital | Michael Garron Hospital | Unity Health Toronto | The Ottawa Hospital | Northwestern Memorial Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Mount Sinai Hospital, Canada \/ Sault Area Hospital | Michael Garron Hospital | Unity Health Toronto | The Ottawa Hospital | Northwestern Memorial Hospital"},{"orgOrder":0,"company":"University of Toronto","sponsor":"Virna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Toronto \/ Virna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University of Toronto \/ Virna Therapeutics"},{"orgOrder":0,"company":"Ochsner Health System","sponsor":"PROCTER AND GAMBLE","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ochsner Health System","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ochsner Health System \/ PROCTER AND GAMBLE","highestDevelopmentStatusID":"1","companyTruncated":"Ochsner Health System \/ PROCTER AND GAMBLE"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"OrthoCarolina Research Institute | University of Arkansas | OrthoMichigan | NYU School of Medicine | Sinai Hospital | MedStar Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Maryland, Baltimore \/ OrthoCarolina Research Institute | University of Arkansas | OrthoMichigan | NYU School of Medicine | Sinai Hospital | MedStar Health","highestDevelopmentStatusID":"1","companyTruncated":"University of Maryland, Baltimore \/ OrthoCarolina Research Institute | University of Arkansas | OrthoMichigan | NYU School of Medicine | Sinai Hospital | MedStar Health"},{"orgOrder":0,"company":"Interleukin Genetics, Inc.","sponsor":"Duke University | Kaiser Permanente","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Interleukin Genetics, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Interleukin Genetics, Inc. \/ Duke University | Kaiser Permanente","highestDevelopmentStatusID":"1","companyTruncated":"Interleukin Genetics, Inc. \/ Duke University | Kaiser Permanente"},{"orgOrder":0,"company":"Harvard University","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Harvard University","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Harvard University \/ AbbVie Inc","highestDevelopmentStatusID":"1","companyTruncated":"Harvard University \/ AbbVie Inc"},{"orgOrder":0,"company":"University of Nebraska Medical Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Nebraska Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Nebraska Medical Center \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"University of Nebraska Medical Center \/ Undisclosed"},{"orgOrder":0,"company":"Appalachian State University","sponsor":"Gaia Herbs Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Appalachian State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appalachian State University \/ Gaia Herbs Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Appalachian State University \/ Gaia Herbs Inc."},{"orgOrder":0,"company":"Dallas VA Medical Center","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dallas VA Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dallas VA Medical Center \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Dallas VA Medical Center \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"USANA Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"USANA Health Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"USANA Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"USANA Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ Hoth Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Virginia Commonwealth University \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Research Center","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fred Hutchinson Cancer Research Center","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Fred Hutchinson Cancer Research Center \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Fred Hutchinson Cancer Research Center \/ National Institutes of Health"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Titan Pharmaceuticals Inc \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"GigaGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GigaGen \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"GigaGen \/ Undisclosed"},{"orgOrder":0,"company":"Auro Vaccines","sponsor":"Hilleman Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Auro Vaccines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Auro Vaccines \/ Hilleman Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Auro Vaccines \/ Hilleman Laboratories"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Israeli Phage Therapy Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adaptive Phage Therapeutics \/ Israeli Phage Therapy Center","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive Phage Therapeutics \/ Israeli Phage Therapy Center"},{"orgOrder":0,"company":"UCLA","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"UCLA","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"UCLA \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"UCLA \/ National Institutes of Health"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vir Biotechnology","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Vir Biotechnology \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Ennaid Therapeutics","sponsor":"Strides Pharma Science","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ennaid Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ennaid Therapeutics \/ Strides Pharma Science","highestDevelopmentStatusID":"1","companyTruncated":"Ennaid Therapeutics \/ Strides Pharma Science"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Pharmavite","sponsor":"Atlantia Food Clinical Trials Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ Atlantia Food Clinical Trials Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Pharmavite \/ Atlantia Food Clinical Trials Ltd."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emergent BioSolutions","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Alnylam Pharmaceuticals \/ Vir Biotechnology"},{"orgOrder":0,"company":"Biogen","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Biogen \/ Vir Biotechnology"},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chromocell Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chromocell Corporation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chromocell Corporation \/ Undisclosed"},{"orgOrder":0,"company":"A2A Pharmaceuticals","sponsor":"LAXAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"A2A Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"A2A Pharmaceuticals \/ LAXAI Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"A2A Pharmaceuticals \/ LAXAI Life Sciences"},{"orgOrder":0,"company":"Macromoltek","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Macromoltek","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Macromoltek \/ Cytovia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Macromoltek \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Felix Biotechnology","sponsor":"The National Science Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Felix Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Felix Biotechnology \/ The National Science Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Felix Biotechnology \/ The National Science Foundation"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0.10000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Plex Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Plex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plex Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Plex Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"BioDuro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BioDuro","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioDuro \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioDuro \/ Undisclosed"},{"orgOrder":0,"company":"Mercaptor Discoveries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mercaptor Discoveries","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercaptor Discoveries \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Mercaptor Discoveries \/ Undisclosed"},{"orgOrder":0,"company":"ThermoGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ThermoGenesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ThermoGenesis \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ThermoGenesis \/ Undisclosed"},{"orgOrder":0,"company":"Xencor","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Xencor \/ Vir Biotechnology"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"University of Georgia","sponsor":"CEL-SCI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Georgia \/ CEL-SCI","highestDevelopmentStatusID":"1","companyTruncated":"University of Georgia \/ CEL-SCI"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaCell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BriaCell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Continuus Pharmaceuticals","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Continuus Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Continuus Pharmaceuticals \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Continuus Pharmaceuticals \/ Department of Defense"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enanta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Enanta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generation Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generation Bio \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Generation Bio \/ Vir Biotechnology"},{"orgOrder":0,"company":"Celularity","sponsor":"Kleo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celularity \/ Kleo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Celularity \/ Kleo Pharmaceuticals"},{"orgOrder":0,"company":"iBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"iBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iBio \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ Undisclosed"},{"orgOrder":0,"company":"Southwest Research Institute","sponsor":"Henry M. Jackson Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Southwest Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Southwest Research Institute \/ Henry M. Jackson Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Southwest Research Institute \/ Henry M. Jackson Foundation"},{"orgOrder":0,"company":"Vyripharm Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vyripharm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vyripharm Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vyripharm Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kaiser Permanente Washington Health Research","sponsor":"Civica Rx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kaiser Permanente Washington Health Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaiser Permanente Washington Health Research \/ Civica Rx","highestDevelopmentStatusID":"1","companyTruncated":"Kaiser Permanente Washington Health Research \/ Civica Rx"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive Phage Therapeutics \/ Department of Defense"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"Codexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Codexis","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Codexis \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"Codexis \/ GSK"},{"orgOrder":0,"company":"Arranta Bio","sponsor":"Recipharm AB","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Arranta Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arranta Bio \/ Recipharm AB","highestDevelopmentStatusID":"1","companyTruncated":"Arranta Bio \/ Recipharm AB"},{"orgOrder":0,"company":"Precisio Biotix Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Precisio Biotix Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precisio Biotix Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":"1","companyTruncated":"Precisio Biotix Therapeutics \/ Mayo Clinic"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sirnaomics \/ Undisclosed"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"The International Vaccine Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TriLink BioTechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriLink BioTechnologies \/ The International Vaccine Institute","highestDevelopmentStatusID":"1","companyTruncated":"TriLink BioTechnologies \/ The International Vaccine Institute"},{"orgOrder":0,"company":"Undisclosed","sponsor":"AIkido Pharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Undisclosed \/ AIkido Pharm","highestDevelopmentStatusID":"1","companyTruncated":"Undisclosed \/ AIkido Pharm"},{"orgOrder":0,"company":"RSUP Persahabatan","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"RSUP Persahabatan","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RSUP Persahabatan \/ Otsuka Holdings","highestDevelopmentStatusID":"1","companyTruncated":"RSUP Persahabatan \/ Otsuka Holdings"},{"orgOrder":0,"company":"Bioithas SL","sponsor":"Centro Sperimentale del Latte S.r.l.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Lacticaseibacillus Rhamnosus","moa":"Microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bioithas SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioithas SL \/ Centro Sperimentale del Latte S.r.l.","highestDevelopmentStatusID":"1","companyTruncated":"Bioithas SL \/ Centro Sperimentale del Latte S.r.l."}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bioiberica

                            Spain
                            Aquaexpo
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothBioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioiberica Joins a European Project to Develop Treatments for Complex Wounds

                            Details : Aim is to develop innovative multifunctional biomaterials to heal wounds using affordable EU-based manufacturing technologies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 18, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Bioiberica Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dr. Reddy's Laboratories

                            India
                            CPhI WW Frankfurt
                            Booth #9.1B48
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : DNDi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services and DNDi To Explore Joint Opportunities to Develop ...

                            Details : MoU aims to bring together DNDi’s expertise in NTDs with the scientific, technical and commercial capabilities of APSL and Dr. Reddy’s. The parties will explore a potential collaboration to develop and market novel and improved drugs for the treatmen...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 30, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : DNDi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Evonik

                            Germany
                            CPhI WW Frankfurt
                            Booth #5.1A24
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothEvonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : BARDA

                            Deal Size : $220.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Evonik Invests US$220 Million in Partnership with The U.S. Government to Build New Lipid Production Facility F...

                            Details : Lipids, molecules that make up the building blocks of living cells, are critical to producing mRNA-based drugs. The mRNA is enclosed in a lipid nanoparticle (LNP) composed of specific lipids. The LNP protects the mRNA and delivers it safely into the cell...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 02, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : BARDA

                            Deal Size : $220.0 million

                            Deal Type : Funding

                            Evonik company banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alchem International Private Ltd

                            India
                            CPhI WW Frankfurt
                            Booth #11.0C48
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothAlchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

                            Lead Product(s) : Curcuminoid,Ellagic acid,Gingerol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : AIIMS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AIIMS Patna Confirms efficacy of AlchemLife’s Phytorelief a Natural Anti-Viral for Mild to Moderate Covid-19...

                            Details : After ten days of treatment with Phytorelief along with standard management, 83% of Covid-19 patients, with mild or moderate symptoms, turned negative in a trial conduct in AIIMS Patna.

                            Product Name : Phytorelief-CC

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            June 10, 2021

                            Lead Product(s) : Curcuminoid,Ellagic acid,Gingerol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : AIIMS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Alchem

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sanofi to Enroll Thousands for its Coronavirus Vaccine Trials

                            Details : Sanofi is working on two vaccine projects to prevent COVID-19. Of more than 100 vaccine candidates in development, 10 have reached the clinical testing stage so far.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 06, 2020

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : GSK

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sanofi and Gsk to Join Forces in Unprecedented Vaccine Collaboration to Fight Covid-19

                            Details : Sanofi will contribute its S-protein COVID-19 antigen and GSK will contribute its proven pandemic adjuvant technology to the collaboration.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 14, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : GSK

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : mRNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19

                            Details : Translate Bio will use its mRNA platform to discover, design, and manufacture a range of SARS-CoV-2 vaccines. Sanofi will provide deep expertise and support from its external research networks.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 27, 2020

                            Lead Product(s) : mRNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lopinavir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie’s HIV drug combo shows no benefit in Covid-19 trial

                            Details : The primary endpoint was the time to clinical improvement. The medication failed to improve the condition or prevent the death of severely-affected Covid-19 patients, compared to standard care.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 19, 2020

                            Lead Product(s) : Lopinavir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lopinavir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : European Health Authorities

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            AbbVie Partnering with Global Authorities

                            Details : The company is collaborating with select health authorities and institutions globally to determine antiviral activity as well as efficacy and safety of lopinavir/ritonavir against COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 09, 2020

                            Lead Product(s) : Lopinavir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : European Health Authorities

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : SARS Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : BARDA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sanofi joins forces with U.S. Department of Health for COVID-19

                            Details : Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi’s well-established recombinant technology platform to expedite a potential COVID-19 vaccine.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 18, 2020

                            Lead Product(s) : SARS Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : BARDA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth